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ABSTRACT 
DNA methylation, histone modifications and chromatin remodelling are the three most 
important epigenetic mechanisms that can affect the regulation of gene activity. These 
mechanisms are often misregulated in human cancers where they affect oncogenes and 
tumour suppressor genes. DNA methylation can, catalyzed by DNA methyltransferases, 
attach methyl groups to the DNA strand. This can either enhance or repress transcription of 
genes, depending of the area of methylation. Histone modifications, including acetylation, 
phosphorylation, methylation and ubiquitylation, can change the conformation of the 
nucleosomes. These modifications determine the folds of the chromatin and thereby which 
genes are available for transcription. Finally, ATP-dependent chromatin remodelling can also, 
by the use of different complexes, change the chromatin structure in order to give access to or 
inhibit transcription factors from binding. Even though the three mechanisms are well 
investigated, it has usually been done separately, thus the correlation between them has not 
yet been comprehended. Some interactions, such as a connection between histone 
deacetylation and DNA methylation in inactivated genes, have however been observed. 
If the epigenetic pattern is changed it can result in carcinogenesis. Contrary to genetic 
changes, these epigenetic changes are reversible. Therefore studies on epigenetics have 
become of great interest in the treatment of cancer. The field of epigenetic therapy has 
expanded and several epigenetic drugs have been synthesized, but the majority of them have 
shown to be toxic and this limits the number of approved drugs. Furthermore, treatment that 
only relies on epigenetic drugs might still be insufficient, since cancer usually is caused by 
several defects in the cell, normally including both genetic and epigenetic changes. Thus 
restoring the epigenetic pattern will not necessarily be a cure for cancer. However, the 
epigenetic patterns have the potential to serve as biomarkers in the diagnostics of cancer. 
Especially some DNA methylation patterns have shown explicit differences between normal 
and cancer cells, which make them suitable as biomarkers. The prospects of epigenetic 
biomarkers in diagnostics and prognostics of cancer seem promising, but further research has 
to be performed before the different epigenetic mechanisms and how they are combined, can 
be fully understood.  
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ABSTRAKT 
De mest betydningsfulde epigenetiske mekanismer, som påvirker reguleringen af 
genaktiviteten, er DNA metylering, kromatin remodellering og histon modifikationer. 
Misregulering af disse mekanismer kan påvirke oncogener og tumorsuppressor gener, hvilket 
ofte kan resultere i cancer. DNA metylering er katalyseret af DNA methyltransferaser, som 
binder metylgrupper til DNA strengen. Afhængigt af hvor i genomet dette sker, kan 
metyleringen enten fremme eller hæmme gentransskriptionen. Histon modifikationer, 
herunder acetylering, fosforylering, metylering og ubiquitylering, kan ændre nukleosomernes 
konfiguration. Disse modifikationer bestemmer kromatinets foldning og dermed hvilke gener 
der er tilgængelige for transskription. ATP-afhængig kromatin remodellering kan også ændre 
kromatin strukturen. Dette sker ved hjælp af forskellige komplekser, som giver adgang til, 
eller forhindrer transskriptionsfaktorerne i at binde sig til DNA strengen. Selvom der har 
været forsket meget indenfor epigenetik, er de tre mekanismer oftest blevet undersøgt 
uafhængigt af hinanden, og sammenhængen mellem dem er dermed ikke fuldt forstået. Visse 
interaktioner, så som en forbindelse mellem histon deacetylering og DNA metylering, er dog 
observeret. 
Hvis det epigenetiske mønster ændres, kan det resultere i carcinogenese. Modsat genetiske 
ændringer er epigenetiske ændringer reversible, og dette har ført til øget interesse indenfor 
epigenetik i forbindelse med cancerterapi. Syntetisering af lægemidler rettet mod epigenetiske 
mekanismer er derfor tiltaget, men de fleste af disse lægemidler har vist sig at være giftige og 
kun få er derfor blevet godkendt til behandling. En eventuel behandling udelukkende med 
brug af epigenetiske lægemidler vil muligvis stadig være utilstrækkelig. Dette skyldes at 
cancer som regel er forårsaget af flere forskellige defekter i cellen, som normalt inkluderer 
både genetiske og epigenetiske ændringer. Gendannelse af det epigenetiske mønster vil derfor 
ikke nødvendigvis være en tilstrækkelig behandlingsmetode. Mønsteret har imidlertid vist sig 
at have potentiale som biomarkør i diagnosticeringen af cancer. Specielt er visse DNA 
metyleringsmønstre i cancerceller signifikant forskellige fra normale celler, hvilket gør 
mønstrene egnede som biomarkører. Udsigterne til at benytte epigenetiske biomarkører i 
diagnose og prognose af cancer ser lovende ud, men hvis der skal opnås grundig forståelse for 
de forskellige epigenetiske mekanismer og deres sammenspil, er videre forskning nødvendig. 
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The report addresses people with the intention to get a general introduction to the mechanisms 
of epigenetics, especially in connection to the development of cancer. The reader should as a 
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Complete names of the abbreviations will be given the first time mentioned, but genes will 
only be called by their abbreviations. Complete names for all abbreviations, including genes, 
can be found in Appendix I.  
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INTRODUCTION 
Traditionally it is said that genes are the blueprint for our phenotype (Campbell, Reece 2005), 
but this raises a question; if all cells in the body contain the same genes, why do all cells not 
look alike?  
In 1942 Conrad Hal Waddington was the first to introduce a term describing this cell 
differentiation. He called it epigenetics; epi meaning over, so above genetics. Originally, 
epigenetics described all the regulatory processes by which a fertilized egg became a fully 
developed mammal (Roloff, Nuber 2005). This was before the discovery of the DNA double 
helix and the use of advanced biotechnologies, so Waddington did not know any of the 
underlying mechanisms of his theory about epigenetics (Allis 2007). In the 1990s these 
mechanisms had been under thorough investigation, and the general definition of epigenetics 
were changed (Roloff, Nuber 2005). The current meaning of epigenetic is heritable changes in 
the properties of the cell, which do not change the underlying DNA sequence (Peedicayil 
2006). This definition covers the expansion of the epigenetic subject, to include other 
processes, such as gene regulation (Allis 2007).  
In 1983 epigenetic changes were discovered to be involved in human cancer (Peedicayil 
2006). Since then, the role of epigenetics in cancer development has been subject to much 
research (Allis 2007). Through many years gene mutations were thought to be the sole cause 
of cancer development (Campbell, Reece 2005). As investigation in cancer progressed, it 
became clear that epigenetic changes also are present during the development of cancer in 
almost every type of tumour (Jones, Baylin 2002). This resulted in a new perspective of the 
disease, since many of the epigenetic changes, unlike gene mutations, are reversible (Allis 
2007). This gave rise to the idea about epigenetic therapy and some epigenetic drugs have 
already been synthesized. The usage of epigenetic therapy in the treatment of cancer has 
however been prolonged, because of big gaps in our knowledge of the subject (Jones, Baylin 
2007).  
AIM OF THE REPORT 
What is the mechanism of DNA methylation and in which ways does it interact with histone 
modifications and chromatin remodelling, in causing cancer? How can the knowledge about 
these epigenetic changes be used in cancer diagnostic and treatment?  
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EPIGENETICS 
The specificity of each cell type in the human body is by most parts caused by a mechanism, 
for regulation of gene activity, called epigenetic regulation (Epigenetics 2007). This is defined 
as heritable changes in gene expression that are not accompanied by changes in the DNA 
sequence (Jones, Baylin 2007) or the sequence of the proteins associated with the DNA 
(Tollefsbol 2009).  
To understand the mechanisms of 
epigenetic regulations it is necessary to 
know the configuration of the genome, 
since this is the target of epigenetic 
marks. The packaging of DNA in 
eukaryotic cells, involves complex 
formation between DNA, core histones 
and other proteins, to form chromatin 
(Tollefsbol 2009). DNA, histones and 
chromatin structure are related, as the 
DNA is wrapped around histones to form 
nucleosomes which then are tightly 
packed into chromatin, see Figure 1  
(Lund 2009).  
Epigenetic regulation can happen on 
many levels, but in correlation with 
cancer the most important aspects of 
epigenetics are DNA methylation, histone 
modifications and chromatin remodelling 
(Tost 2008). The mechanism of DNA 
methylation is when methyl groups are added to the DNA, which normally takes place at the 
cytosine bases (Tost 2008). Histone modifications are changes in the properties of the 
histones, such as charge, shape (Lehninger, Nelson et al. 2008) and size (Allis 2007). 
Chromatin remodelling is a change in chromatin structure, performed by different complexes 
(Kundu, Dasgupta 2007). The specific combination of all the epigenetic marks in a cell is 
termed the epigenetic code. Epigenetic alterations change the interactions between DNA and 
Figure 1: The DNA helix is wrapped around  histones to
form nucleosomes, which is further packed into 
chromatin. Modified after (Lund University 2009) 
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proteins, causing some parts of the DNA structure to open and some to close. Dependent on 
the alteration, it can either entail transcriptional silencing of the modified allele (Rakyan, 
Preis et al. 2001) or enhance the possibility or rate of transcription (Grant 2001). The 
silencing of genes at the chromatin level is essential for eukaryotic organisms when they 
organize important biological processes such as differentiation, imprinting and silencing of 
large chromosomal domains. This is for example important in female mammals, due to 
silencing of one of the X chromosomes (Jones, Baylin 2007). Epigenetic modifications can be 
inherited through several mitotic cell replications (Rakyan, Preis et al. 2001), but the 
methylation patterns are not always maintained through each cell division (Clark, Melki 
2002). Previously, it was assumed that epigenetic modifications were erased at some stage 
during gametogenesis or early embryogenesis to reestablish the totipotency of the developing 
embryo. Studies, however, indicate that epigenetic marks in some mammals are not 
completely erased from parent to offspring (Rakyan, Preis et al. 2001). 
The three different epigenetic mechanisms are all correlated. An example of correlation of 
two mechanisms is the connection between histone deacetylation, which is the removal of 
acetyl groups from the histone tails, and DNA methylation. After DNA methylation certain 
proteins bind to the methylated DNA and activate enzymes responsible for the deacetylation 
of the histones. These events lead to changes in the chromatin structure and thereby gene 
silencing (Campbell, Reece 2005). 
This report will focus on the mechanism of DNA methylation, but first the concepts of histone 
modifications and ATP-dependent chromatin remodelling will be described. This will be 
followed by an examination of the epigenetic alterations in cancer and the possibilities for 
using this in cancer therapy and diagnostics.  
Page 10 of 67 
 
HISTONE MODIFICATIONS 
Histones are proteins that order and pack DNA into structural units called nucleosomes. In all 
eukaryotic cells there are five major classes of histones, which differ in molecular weight and 
amino acid composition (Lehninger, Nelson et al. 
2008). Typically, the nucleosome is composed of 
two copies of each of the four core histones; H2A, 
H2B, H3 and H4 with 146 basepairs of DNA 
wrapped around to form an octamer, see Figure 2 
(Grant 2001). The DNA is sustained around the 
octamer by the fifth protein family H1 (Sørensen, 
Falkenberg et al. 2002). Each of the core histones 
has a structured domain and an unstructured amino 
terminal of 25-40 residues, which are called the 
tail, and extends into the surroundings of the 
nucleosomes (Grant 2001). The state of the 
chromatin is by most part controlled by covalent 
modifications of histone tails. The major modifications are acetylation, phosphorylation, 
methylation and ubiquitylation (Tollefsbol 2009), which affect the net charge, shape or other 
properties of the histones (Lehninger, Nelson et al. 2008). The specific combination of these 
modifications is termed the histone code and determines whether the chromatin is unfolded or 
condensed and thereby whether the genes are turned on or off (Tollefsbol 2009). A figurative 
overview of some of the different histone modification sites can be seen on Figure 3 
(Lehninger, Nelson et al. 2008) and in the following paragraph the different modifications 
will be examine.  
Figure 2: Nucleosome consisting of eight 
core histones forming an octamer. H1 
links the different nucleosomes together. 
Modified after (Sørensen, Falkenberg et 
al. 2002) 
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Figure 3: The flags indicate some of the histone modification sites. In general the marks that activate 
transcription are acetylation (Ac), arginine (R) methylation and some of the lysine (K) methylation. 
Repressive lysine methylation includes H3K9, H3K27 and H4K20 (Allis 2007). 
 
Histone acetylation 
Histone modifications by acetylation and deacetylation have been associated with 
transcriptional activity, regulated by changes in the nucleosome assembly and higher-order 
chromatin structure (Grant 2001). Histone acetylation involves the attachment of an acetyl 
group from acetyl-CoA to the ε-amino group of the specific lysine (K) side chains (Tollefsbol 
2009) and is carried out by the enzyme histone acetyltransferase (HAT) (Chung 2002). Most 
often the acetylated lysines are H3K9, H3K14, H3K18, H3K23, H4K5, H4K8, H4K12 and 
H4K16. In some cases acetylation can also occur at serine (S) or arginine (R) residues. The 
attachment changes the positively charged residue on lysine into a negatively charged residue, 
which results in the histones having a decreased affinity for DNA. The consequence is that the 
chromatin structure opens and the DNA is thereby more accessible for transcription 
(Tollefsbol 2009). The reverse, deacetylation, catalyzed by histone deacetylases (HDAC) 
(Chung 2002), removes the acetyl groups, which results in increased affinity for the DNA. 
The chromatin become more condense and is thereby less accessible for transcription, see 
Figure 4 (Tollefsbol 2009). The modification can either be global, involving large parts of the 
chromatin, or promoter specific. The global histone acetylation concerns the general 
transcriptional activity, while the promoter specific acetylation is important for specific gene 
activity (Vaissiere, Sawan et al. 2008). 
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Figure 4: Acetylation of the histone tails is catalyzed by histone acetyltransferase (HAT). Acetylation 
activates gene expression by making the chromatin structure less dense. Deacetylation is carried out by the 
enzyme histone deacetylase (HDAC) and results in a denser chromatin structure, and therefore no gene 
expression. Modified after (Yoshida 2008). 
 
The effect of histone acetylation is not restricted to change chromatin structure, it also affects 
the interaction between the target DNA of the chromatin and the regulatory proteins involved 
in transcription. The level of acetylation is not evenly distributed over the chromatin. Most of 
the genome has a low level of acetylation, secured through equilibrium between HAT and 
HDAC activity. Gene expression is therefore regulated by the distribution of acetylation and 
changes in the prevalence of acetylation can induce other epigenetic modifications. An 
example of this could be deacetylation by HDAC, which may entail DNA methylation, 
thereby leading to a pre-neoplastic state, see Figure 5. Further, deacetylation and DNA 
methylation cause the chromatin to condense, which can induce permanent gene silencing 
(Vaissiere, Sawan et al. 2008). If silencing occurs in e.g. the promoter region of tumour 
suppressor genes, it will disrupt or change normal cell activity and can lead to cancer 
(Tollefsbol 2009). 
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Figure 5: In normal tissues the promoter regions of the DNA tend to be unmethylated and the histone tails 
acetylated, thereby resulting in a gene product. In pre-neoplastic tissue the acetylation level is lower which 
entail DNA methylation, resulting in a weak gene product. In tumour tissue the histone tails are completely 
deacetylated and the DNA is methylated. This results in a dense chromatin structure and thereby no gene 
product (Vaissiere, Sawan et al. 2008) 
 
Histone phosphorylation 
Another form of histone modification is phosphorylation, which influences processes such as 
transcription, DNA repair, apoptosis and chromatin condensation (Grant 2001). 
Phosphorylation is induced by aurora kinases at the serines on H3S10 and H3S28. The 
efficiency of the phosphorylation depends on the type of aurora kinase (Tollefsbol 2009). 
Mammals have three different kinds of aurora kinases; A, B and C (Vadera, Lens 2008). In 
mitosis the phosphorylation has an essential role, because it correlates with chromosome 
condensation (Hsu, Sun et al. 2000). The negatively charged phosphate groups are thought to 
neutralize the charge of the histone tails, resulting in reduced affinity towards the DNA. 
Studies furthermore indicate that phosphorylation of H3S10 induces HAT activity, leading to 
an additional increase in transcription activity, caused by acetylation (Grant 2001). The 
survival of a cell depends on the accuracy of mitosis and misregulation or errors can therefore 
provide the source of genomic instability that typically is associated with tumourigenesis 
(Keen, Taylor 2004). Especially over-expression of the aurora kinase A is displayed in many 
kinds of tumours and has a well documented oncogenic function. The involvement of the 
other aurora kinases in cancer development is less clear, but aurora B has been reported to be 
over-expressed in certain tumour types (Vadera, Lens 2008). 
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Histone methylation 
Transcriptional activity is also regulated by histone methylation (Grant 2001), but this form of 
histone modification is more complex than the others, since it can occur on both lysine and 
arginine (Allis 2007). The methylation is catalyzed by the histone methyltransferases 
(HMTs), which transfer a methyl group from the methyl donor S-adenosyl-L-methionine 
(SAM) to the residues. SAM will later be encountered in the DNA methylation paragraph. 
The HMTs play a crucial role in cancer development, since most of them function as tumour 
suppressors (Tollefsbol 2009). Depending on the residue getting methylated, histone 
methylation can either enhance or repress transcriptional expression. There are at least 24 
identified sites of lysine and arginine methylation on the core histones. These residues have 
several methylated states, which add another level of complexity (Allis 2007). Arginine can 
be either mono- or dimethylated, while lysines can be mono-, di- and trimethylated (Völkela, 
Angrand 2006). This gives numerous combination possibilities, which are applicable in 
tightly regulated processes, such as transcription (Allis 2007).  
There are six well characterized lysine methylation sites: H3K4, H3K9, H3K27, H3K36, 
H3K79 and H4K20. Methylation on H3K4, H3K27 and H3K79 is associated with activation 
of transcription, while the others have been linked to repression (Allis et al., 2007). 
Methylation of H3K9, which entail repression, is thought to play a role in cancer development 
(Chung 2002). A study by Peters et al. (2001), have shown that mice missing Histone-H3-
lysine-9-specific histone methyltransferase (Suv39h HMT), have an increased tumour risk 
and severely impaired development (Peters, O'Carroll et al. 2001).  
Arginine methylation is present at a very low frequency (Davie, Dent 2002), but has, 
however, been linked with transcriptional activity (Völkela, Angrand 2006) when H4R3, 
H3R2, H3R17 and H3R26 are methylated. Arginine methylation can in contrast also cause 
repression, which happens when H3R8 and H3R3 become methylated (Allis et al., 2007).  
 
Histone ubiquitylation 
Ubiquitylation (Ub) is different from the other types of histone alterations, mainly because of 
its size. Ub is a large polypeptide which increases the size, of the histone by approximately 
two-thirds. Ub can, as histone methylation, be either repressive or activating, depending on 
which histone it binds to. H2B monoubiquitylation on K123 is activating the DNA 
transcription and leads to H3K4 methylation, whereas H2A monoubiquitylation on K119 is 
repressing the transcription (Allis 2007). 
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An overview of the different histone modifications can be seen in Table 1. 
Table 1: A selection of covalent histone modifications, modified from (Allis 2007). 
Modification Role in transcription Histone-modified sites 
Acetylation Activation H3 – K9, K14, K18, K56 
H4 – K5, K8, K12, K16 
H2B – K6, K7, K16, K17 
Phosphorylation Activation H3 – S10 
Methylation Activation H3 – K4, K36, K79 
 Repression H3 – K9, K27 
H4 – K20 
Ubiquitylation Activation H2B – K123 
 Repression H2A – K119 
  
Recombined changes 
Crucial for the understanding of histone modifications is the ever existing link between both 
the different modifications, but also with the other types of epigenetic changes, such as DNA 
methylation. Furthermore, it is important to realize that one type of modification does not 
always lead to the same result. The location of the change has an essential role in determining 
the final result. An example is the promoter regions of tumour suppressor genes in healthy 
cells. They have enriched histone modification marks, acetylation and methylation, which 
result in active transcription. In other parts of the genome in the healthy cells, such as DNA 
repeats, histone methylation functions as a repressive mark. When the histone code is 
changed, due to loss of the active histone marks on the tumour suppressor gene promoters, 
combined with the loss of the repressive marks on the DNA repeats, the chromatin 
conformation changes, which can result in cancer (Esteller 2007). 
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ATP-DEPENDENT CHROMATIN REMODELLING 
The approximately 50,000-100,000 genes of the human genome result in a DNA strand being 
about 2 meters long. For the DNA to be able to fit into the nucleus, it has to be organized as 
chromatin. The chromatin has a compact structure, and remodelling is therefore required to 
allow access of binding proteins and enzymes involved in e.g. replication and DNA 
transcription (Varga-Weisz, Becker 1998). The overall chromatin remodelling is not only 
carried out by histone modifications, but is also affected by ATP-dependent chromatin 
remodelling complexes (Dinant, Houtsmuller et al. 2008). The importance of these chromatin 
remodelling complexes is apparent, considering that 80% of the nuclear DNA is packaged by 
nucleosomes. For all cell processes involving DNA, like transcription, recombination, 
replication and repair mechanisms, the chromatin needs to be dynamic in order to give access 
to the genes. Chromatin remodelling therefore plays a crucial role in regulation of gene 
expression and misregulations can cause tumourigenesis and some diseases such as X-linked 
mental retardation syndrome (Kundu, Dasgupta 2007). The following paragraph will examine 
the different ATP-depending chromatin remodelling complexes and how these alter the 
chromatin structure.  
DNA interacts with the histones in the nucleosome by forming hydrogen bonds and salt links. 
ATP-dependent chromatin remodelling complexes are able to either break or reform these 
interactions (Kundu, Dasgupta 2007). These complexes use the energy from ATP-hydrolysis 
to change either the structure or the position of the nucleosomes. These ATP-dependent 
changes in the chromatin structure, can help transcription factors and other regulatory 
proteins, which normally would be occluded by the histone proteins, to gain access to DNA 
sequences (Allis 2007). The alterations of chromatin by remodelling complexes can be done 
in four different ways, see Figure 6.  
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Figure 6: Mechanisms for ATP-dependent remodelling. The change in position or composition of the 
nucleosomes is relative to the DNA wrapped around it. a) Nucleosome sliding to expose a region that was 
previously hidden. b) Histone exchange where a histone variant is transferred in to the octamer, instead of a 
standard histone. c) Nucleosome eviction exposes an even larger region of the DNA, with the removal of an 
octamer. d) Altered nucleosome structure where the path of DNA is creating a loop on the surface on the 
nucleosome. Modified after (Allis 2007).    
The first one is sliding of the nucleosome (a), meaning that they are moved along the DNA 
strand (Kundu, Dasgupta 2007). The second way is the exchange of histones within the 
histone octamer (b), so the nucleosome is changed to another variant. The third way, which is 
called nucleosome eviction (c) (Allis 2007), is the transfer of an octamer from one part of the 
DNA to another part (Kundu, Dasgupta 2007). The fourth one alters the path of how the DNA 
is wrapped around the nucleosome, leading to a gap between the surface of the nuclesome and 
the DNA strand (d) (Allis 2007).  
All of the chromatin remodelling complexes contains ATPase subunits to utilize ATP energy. 
These ATPase subunits are all members of the superfamily sucrose nonfermenting 2 (SNF2) 
and they only differ from each other in their protein composition (Vignali, Hassan et al. 
2000). This superfamily can, by their diversities, be divided into four main ATP-dependent 
chromatin remodelling complex groups: Switching/sucrose nonfermenting (SWI/SNF), 
imitation switching (ISWI), nucleosome remodelling histone deacetylase/chromo-helicase 
ATPase DNA binding (NuRD/Mi-2/CHD) and inositol requiring 80 (INO80). All of the ATP-
dependent chromatin remodelling complexes can lead to either transcriptional activation or 
repression. The exact outcome of their remodelling action is based on the context in which 
they are interacting with the chromatin. However, this exact mechanism still needs to be 
clarified. Within the groups the different ATP-dependent remodelling complexes share many 
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of the same subunits. Some of the remodelers also have specific chromatin-interacting 
domains, which suggest that they play a role in specific modifications (Wang, Allis et al. 
2007). Appendix II, shows an overview of the ATP-dependent remodelling complexes, their 
families, subunits and functions. 
 
Switching/sucrose nonfermenting complexes 
Particularly, mammalian SWI/SNF complexes are related to oncogenic formation, because 
they directly interact with tumour suppressors and protooncogenes, such as RB and BRCA1 
(Kundu, Dasgupta 2007).  
SWI/SNF complexes mainly alter nucleosomes by disorganizing and reorganizing their 
positions to let the transcription factors bind to the DNA (Wang, Allis et al. 2007). They are 
generally involved in regulation of transcription by interacting with activating and repressing 
transcription factors (Caramel, Medjkane et al. 2008). SWI/SNF complexes can also transfer 
histone octamers to another part of the chromatin, see Figure 6c (Demeret, Vassetzky et al. 
2001). Mammalian SWI/SNF complexes are related to tumourigenesis, because they directly 
interact with tumour suppressors and protooncogenes, such as RB and BRCA1 (Kundu, 
Dasgupta 2007). All mammalian SWI/SNF complexes have the sucrose nonfermenting 
5/integrase interactor 1 (SNF5/INI1) core subunit (Stein, Pardee 2004). The gene encoding 
SNF5/INI1 is a tumour suppressor gene and it is found nonfunctional in most human 
malignant rhabdoid tumours. These tumours are highly aggressive in early childhood and 
occur in different parts of the body, e.g. central nervous system, kidney or liver (Caramel, 
Medjkane et al. 2008). The SNF5/INI1 is also related to regulation of cell-cycle progression 
and acts in checkpoints, ploidy, and chromosomal stability (Wang, Allis et al. 2007). 
Research has further shown that two catalytic subunits of SWI/SNF complexes, called 
Brahma and Brahma-related gene-1, are involved in tumourigenesis (Wang, Allis et al. 2007) 
 
Imitation switching complexes  
ISWI complexes mainly alter and arrange the organization of nucleosomes to promote 
repression, but they are also found to activate transcription (Wang, Allis et al. 2007). 
Repression and activation of transcription are carried out by nucleosome sliding, see Figure 
6.a, which decrease the affinity between DNA and histones (Demeret, Vassetzky et al. 2001).  
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Nucleosome remodelling histone deacetylase/chromo-helicase ATPase DNA binding 
complexes 
NuRD/Mi-2/CHD complexes, in particular, have influence on transcriptional activation of 
rRNA in the nucleus and act as a mediator to affect repression (Wang, Allis et al. 2007). They 
can also induce chromosome sliding, see Figure 6a (Bao, Shen 2007). These NuRD/Mi/CHD 
complexes contain a domain, which specifically recognizes methylated histone tails. The 
complexes include metastasis tumour antigen 1 (MTA1) and MTA3, which are connected 
with some cancer types. A variation of MTA1 was, for instance, found over-expressed in 
breast cancer, where it inhibits cell signaling by affecting estrogen receptors, thereby 
stimulating tumourigenesis. MTA3 is also linked to breast cancer and is found to interact with 
a transcriptional repressor and a protooncogene (Wang, Allis et al. 2007). 
 
Inositol requiring complexes  
INO80 complexes mediate repression and activation of specific genes and they participate in 
cell cycle checkpoint adaptation (Bao, Shen 2007). INO80 complexes have also shown to 
participate in the double strand break DNA repair system and base excision repair system. 
This shows a connection between the DNA damage response and chromatin remodelling 
(Wang, Allis et al. 2007). 
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DNA METHYLATION 
DNA methylation changes the interactions between proteins and DNA, which can lead to 
alterations in chromatin structure and either a decrease or an increase in the rate of 
transcription (Jones, Takai 2001). All healthy cells contain DNA, which, to some degree, is 
methylated. Changes in the normal pattern of methylation contribute to the development of 
cancer (Tost 2008). Hypermethylation is an increase in the number of methyl groups on the 
DNA strand and is often linked to gene mutations and gene silencing. Hypomethylation is a 
decrease in the amount of the methylated DNA and is linked to DNA instability and 
activation of genes that are normally silenced, such as oncogenes in cancer cells (Clark, Melki 
2002). Methylation is a regulatory mechanism involved in both initiation of transcription and 
silencing of genes, depending on the type of methylation and the gene that is methylated (Tost 
2008). Repression caused by DNA methylation can happen directly or elaborately. The direct 
way is when the methyl groups inhibit the transcription factors from binding to the promoter 
region. The elaborate way represses DNA expression with the use of other chromatin 
modifying factors, which bind to methylated CpGs (Bogdanovic, Veenstra 2009). CpG is an 
abbreviation for cytosine and guanine separated by a phophate and is derived from the way 
they are connected in the DNA strands (Allis 2007). This paragraph will introduce the 
different factors, which influence the DNA methylation and examine the consequences of the 
resulting methylation pattern. Finally the effects of abnormal DNA methylation, such as 
hypo- and hypermethylation, will be elaborated. 
 
In mammals the methyl group binds to the 5-position of cytosine (Jones, Takai 2001) forming 
a 5-methylcytosine (m5C) residue, which is a minor base in the DNA, see Figure 7 
(Vanyushin 2005). This is often occurring in the major groove in the double helix, where the 
methyl groups extend from the dense part of the helix. The attachment alters the structural 
conformation of the DNA strand. This causes the binding of proteins that either inhibits or 
enhances transcription of the DNA (Jones, Takai 2001).  
 
Figure 7: The methylation takes place on the 5-carbon in cytosine (Laboratory 2007) 
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CPG-ISLANDS 
Of the CpGs present in our genome approximately 70 % are methylated. This is however not 
the case in most of the CpG dense DNA (Feltus, Lee et al. 2003). The unmethylated, CpG 
rich areas are called CpG islands and are up to a few kb in length (Strathdee, Sim et al. 2004). 
The definition of CpG islands is under constant reevaluation, and today the more generally 
accepted rules (Tost 2008), suggested by Takai and Jones (2002), are that the length should be 
more than 500 bp, the content of CG more than 55 % and the observed versus the expected 
ratio of CpG should at least extend 0,65 (Takai, Jones 2002). The high boundaries of the 
definition are set as an attempt to eliminate the areas with small exonic regions and some 
repetitive DNA sequences (Jones, Takai 2001). CpG islands are often associated with 
housekeeping genes, mapping the promoter or the first exon of the gene and located in the 5’ 
untranslated region, but they also occur in tissue specific genes and can occasionally be found 
within the body of the gene or in the 3’ region (Esteller 2002). Because of their important 
location, CpG islands are critical in gene expression regulation and cell differentiation (Wang, 
Leung 2004). This regulatory mechanism is used in genomic imprinting and X-chromosome 
inactivation, where the CpG islands are methylated (Fazzari, Greally 2004). The CpG island 
on the active X-chromosome is, on the contrary, unmethylated, which allows the genes to be 
expressed (Cross, Bird 2005). 
 
DNA METHYLTRANSFERASES 
Addition of a methyl group to a CpG dinucleotide, 
needs the action of DNA methyltransferases 
(DNMTs) (Clark, Melki 2002). There are five known 
DNMTs in mammals; DNMT1, DNMT2, DNMT3a, 
DNMT3b and DNMT3L (Robertson 2009). The 
DNMTs all use SAM as a methyl donor; see Figure 8 
and Figure 9 (Cheng 1995). The 5-position of 
cytosine is rather unreactive, so the methyl group 
does not directly bind to the cytosine. The actual 
binding process is not fully understood, but researchers propose that the binding takes place 
as illustrated in Figure 9 (Bestor 2000). First the thiol group, from a cysteine, binds to the 
Figure 8: S-adenosyl-L-methionine
(SAM) is used as the methyl donor in
DNA methylation (Robertson 2009a). 
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DNMT and then to the 6-position carbon (Cheng 1995). Accordingly the N in the 3-position 
becomes protonated and the double bond moves. The new double bond makes a reactive 
enamine (-C=C-N-), which then attracts the methyl group of SAM. After the methyl group 
transfer, the proton is detached, and then the double bond between the 5 and 6-carbon is 
reformed and the S-DNMT is released. The cytosine residue is now methylated (Bestor 2000).  
 
Figure 9: The binding of the methyl group. In (1) the DNMT binds to the thiol group of a cysteine and then 
the complex binds to the 6-position carbon. Right after, in (2), the 3-position nitrogen becomes protonated and 
the double bond moves. The formation of the new double bond makes an enamine, which attracts the methyl 
group. In (3) the methyl group binds to the 5-position carbon and the proton is released, furthermore the 
double bond moves back between the 3 and 4 positioned carbons. In (4) DNMT and the thiol group is released 
and the 5-6 position double bond is reformed (Bestor 2000). 
Even though the methylation is not integrated into the DNA strand,  the semi-conservative 
replication ensures that the methylation pattern consists through cell division. The DNMTs 
are thereby involved in two different kinds of methylation; one that methylates unmethylated 
DNA strands, de novo methylation, and one 
that methylates hemimethylated DNA 
strands, maintenance methylation, see 
Figure 10. After DNA replication, the DNA 
is hemimethylated; the template strand is 
still methylated, but the complementary 
strand is not. The complementary strand 
becomes methylated with maintenance 
methylation, where the DNMT1 is 
necessary (Allis 2007). DNMT3a and 
DNMT3b catalyze de novo DNA 
methylation. Experiments have shown that 
an inactivation of either DNMT1, DNMT3a or DNMT3b is lethal in mice, which suggest that 
DNA methylation has a vital function in mammals (Clark, Melki 2002).  
Figure 10 De novo methylation and maintenance 
methylation in DNA. Spheres represent methylated 
cytosines (Allis 2007). 
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Figure 10 is a simplification, because no mammalian DNMTs have been shown to be specific 
for one reaction. DNMT1 is for example also part of de novo methylation, but has higher 
affinity for the maintenance methylation process (Bestor 2000). In fact, DNMT1 has a higher 
de novo activity than DNMT3a and DNMT3b, which are usually related to de novo 
methylation, but when DNMT1 is combined with them, their de novo activity is increased. 
Likewise, investigations have shown that DNMT3a and DNMT3b do not only function in de 
novo methylation, but also participate in maintenance methylation along with DNMT1 (Tost 
2008).  
The DNMTs are generally believed to consist of a regulatory domain in the N-terminal and a 
catalytic domain in the C-terminal, see Figure 11 (Robertson 2009). The N-terminal is mostly 
involved in protein-protein interactions and subcellular localization (Tost 2008). The domains 
positioned in this region differ to a certain extent between the enzymes, whereas the C-
terminals share 6 out of 10 motifs (Turek-Plewa, Jagodzinski 2005). This differentiation 
within the DNMTs is very likely to cause the different methylation properties of the enzymes. 
 
 
Figure 11: The structure of mammalian DNA methyltransferases (DNMTs). The regulatory N-terminal and the 
catalytic C-terminal, both contain several domains that differ within the different DNMTs. This is illustrated 
by ribbons with different patterns and roman numbers, respectively. Only the shared domains of the C-
terminal are shown here: I and X is required to form S-adenosyl-L-methionine binding site. IV is located in 
the active site where it binds to substrates and VI has a residue, which act as a proton donor. IX is necessary 
to sustain substrate binding site formation and the function of VIII is not yet understood. Modified after 
(Turek-Plewa, Jagodzinski 2005). 
 
DNMT1 contains the largest N-terminal, compared to the other methyltransferases. It has 
been shown to be necessary for catalytic activity, due to intramolecular interactions between 
the C and N terminal (Tost 2008). Agoston et al. (2005) have furthermore shown that the 120 
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amino acids of the N-terminal are necessary in the degradation of DNMT1. They discovered 
that in breast cancer, the enzymes were lacking this specific amino acid sequence and that the 
level of DNMT1 was increased, without an increase in DNMT1 mRNA. This suggests that the 
enzyme responsible for the degradation of DNMT1 uses the N-terminal as a destruction 
domain (Agoston, Argani et al. 2005), 
Even though DNMT2 shares the same catalytic DNMT motif sequence as the others 
(Schaefer, Lyko 2009), it only shows a weak DNMT activity and the loss of this enzyme does 
not have severe consequences (Allis 2007). Studies, using both a genetic and biological 
approach, have shown that DNMT2 methylates small RNA rather than DNA (Schaefer, Lyko 
2009). 
DNMT3a has been shown to bind non-specific to DNA, but generally it binds to CpG 
dinucleotides. Unlike DNMT1, the catalytic domain of DNMT3a, as well as DNMT3b, 
performs methyltransferase activity independent of the N-terminal. All three DNMTs are 
transcriptional repressors and have been shown to interact with HDAC (Tost 2008).  
DNA methyltransferase 3-Like (DNMT3L) is part of the DNMT3 family even though it is 
catalytically inactive. It is therefore not thought to exhibit any DNMT activity. DNMT3L has 
been shown to stimulate DNMT3a and DNMT3b by direct interaction, thereby regulating 
their catalytic activity. DNMT3L has further shown necessity for the establishment of 
genomic imprinting (Suetake, Shinozaki et al. 2004).  
 
Demethylation 
Demethylation in mammals has been proposed to operate in various ways (Ooi, Bestor 2008). 
This paragraph will focus on a certain mechanism, presented by Métivier et al. (2008), which 
researchers find probable (Metivier, Gallais et al. 2008). The demethylation takes place in 
several steps. First the methylated cytosine residue has an oxidative deamination, meaning 
that the amine of the 4-position carbon is changed to oxygen, and thereby the methylated 
cytosine becomes a thymine, see Figure 12 (Ooi, Bestor 2008). 
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Figure 12: An oxidative deamination of the methylated cytosine leads to the formation of thymine (Allis 
2007). 
The deamination gives a T/G mismatch basepair, which can be restored by the DNA repair 
system by removal of the thymine. Then the base excision repair system inserts an 
unmethylated cytosine, thus ending with an unmethylated C/G basepair (Ooi, Bestor 2008). 
The demethylation process is, surprisingly, thought to be initiated by the DNMT3a and 
DNMT3b, which are normally associated with the DNA methylation (Gehring, Reik et al. 
2009). This suggests that DNMT3a and DNMT3b are involved in demethylation and 
methylation, which both are important mechanisms during gene transcription. Absence of the 
methyl donor SAM seems to favour the conversion of methylated cytosine to thymine (Ooi, 
Bestor 2008). 
 
METHYL-CPG-BINDING PROTEINS 
Methyl-CpG-binding proteins (MBPs) are a group of proteins, which all bind to methylated 
CpGs. Their function is to recognise and convey the information that is embedded in the DNA 
by the methylation marks (Tost 2008). When MBPs bind to the methylated CpGs they inhibit 
the transcription factors from binding (Hopkins, Burns et al. 2007). They thereby induce the 
elaborate way of repressing DNA expression, see Figure 13 (Bogdanovic, Veenstra 2009). 
 
Figure 13: Elaborate transcriptional repressing a) Normal transcription initiated by binding of transcription 
factors. b) Gene silencing occurs by association of methyl-CpG-binding domain (MBD) proteins, which 
induce chromatin remodelling leading to a blocked access of the transcription factors (Hopkins, Burns et al. 
2007). 
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The MBPs are important participants in e.g. transcriptional silencing, but this role is not yet 
completely defined. It is debated whether it is the MBPs alone that cause the silencing, or if 
they just maintain the silencing created by some other mechanism. The MBPs can induce 
chromatin changes that sustain the silencing on a long term basis (Prokhortchouk, Hendrich 
2002). The MBPs are subdivided on account of their structure. One family consists of proteins 
that have a methyl-CpG-binding domain (MBD), another group contains a three-zinc-finger 
motif that recognizes methylated DNA and the third group is the SET and RING-associated 
(SRA) domain proteins (Filion, Zhenilo et al. 2006). In the following section the different 
types of MBPs will be presented more thoroughly. 
 
Methyl-CpG-binding Domains 
The MBD family consists of: MBD1, MBD2, MBD3, MBD4 and Methyl-CpG-binding 
protein 2 (MeCP2) (Ballestar, Paz et al. 2003). All these proteins contain the methyl-CpG-
binding domain, which has been shown to assume a very similar fold. The members of the 
MBD family only share the resemblance in the MBD motif, the rest of the protein is quite 
different (Fatemi, Wade 2006). The only exception is MBD2 and MBD3 which are about 
70% identical, see Figure 14 (Tost 2008). 
 
Figure 14: Methyl-CpG-binding protein family. The Methyl-CpG-binding domain (MBD) proteins all contain 
the MBD. MBD1, MBD2 and Methyl-CpG-binding protein 2 (MeCP2) all contain the transcriptional 
repression domain (TRD). The CxxC domain is a zinc-finger motif which gives a possibility for MBD1 to bind 
unmethylated DNA. The * in MBD3 means a slight mutation from the other MBDs. Modified after 
(Bogdanovic, Veenstra 2009). 
In contrast to the other MBDs, MBD3 does not bind specifically to methylated DNA (Tost 
2008). MBD3 is a part of the NuRD/Mi-2/CHD complex (Wang, Allis et al. 2007), which 
when associated with MBD2 can bind to methylated DNA (Ballestar, Paz et al. 2003). MBD2 
and MBD3 can also form a heterodimer that only binds to hemimethylated DNA. 
Experiments with knockout mice have shown that only MBD3 affects embryonic lethality. 
However, lack of the other MBDs showed defects in neurological development and behavior, 
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e.g. mutations in the MeCP2 complex causes Rett Syndrome, which is a relatively common 
mental retardation disorder (Tost 2008). These observations prove the importance of the 
MBDs in brain development. Since the experiment shows that only lack of MBD3 has an 
effect on the viability, it is suggested that there might be other proteins, than the other MBDs, 
that also bind to methylated DNA and repress transcription (Tost 2008). 
MeCP2 prefers to bind to CpGs, which are followed by a run of at least four A/Ts. This might 
be the reason for some of the promoter specificity that MeCP2 exhibits. The MeCP2 complex 
consists of several domains. Two of these domains are active binding sites, one is specific for 
binding methylated DNA, and the other is specific for binding unmethylated DNA. 
Furthermore, MeCP2 contains a transcription repression domain, see Figure 14. This domain 
can interact with DNMT1 and that might indicate that MeCP2 also is involved in maintenance 
of methylation (Tost 2008). 
All the MBDs, except MBD4, can interact with HDACs and induce chromatin modifications, 
resulting in transcriptional silencing (Ballestar, Paz et al. 2003). MBD1s interaction with 
other proteins is not well known, but it seems to bind to proteins involved in histone 
methylation (Fatemi, Wade 2006). 
The MBD4 has since its discovery, been independently identified as a DNA repair protein 
(Prokhortchouk, Hendrich 2002) and is proposed to be a part of the base excision repair 
system (Metivier, Gallais et al. 2008). The function is not methylation dependent, but the 
protein recognizes methylated CpGs and C/T mismatches and take part in the m5C→T 
mutation repair (Tost 2008). The m5C→T mutation occurs when m5C is deaminated, 
whereas deamination of a normal cytosine gives uracil, which is efficiently removed from 
DNA. The mutation frequency for m5C is 10-50 times greater than for other bases 
(Prokhortchouk, Hendrich 2002). MBD4 share MeCP2s preference for binding to CpGs with 
adjacent A/T rich regions (Tost 2008). 
 
Zinc finger proteins 
Another group of proteins that bind to methylated DNA is proteins containing a three-zinc 
finger motif. Until now three such proteins have been identified. The proteins are zinc finger 
and BTB domain-containing protein 4 (ZBTB4), ZBTB38 and kaiso, see Figure 15. The kaiso 
protein binds to methylated CGCGs or the consensus kaiso binding site: TCCTGCNA. 
ZBTB4 and ZBTB38 can bind to single methylated CpGs, but they do not bind any other 
methylated sequences. The three zinc-finger proteins only share these identical sequences; 
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their zinc-fingers and the Poxvirus zinc finger/Bric-a-brac, Tramtrack, Broad-complex 
(POZ/BTB) domain see Figure 15. In experiments the rat homologue of ZBTB38 has been 
shown to activate as well as repress transcription depending on where it binds in the genome 
(Filion, Zhenilo et al. 2006). 
 
Figure 15: Zinc finger proteins. The zinc-finger (ZF) domains are found in kaiso, zinc finger and BTB 
domain-containing protein 4 (ZBTB4) and ZBTB38. They also have Poxvirus zinc finger/Bric-a-brac, 
Tramtrack, Broad-complex (POZ/BTB) domain. Kaiso includes less ZF domains than ZBTB4 and ZBTB38. 
The * in ZBTB4 represents an insertion. Modified after (Bogdanovic, Veenstra 2009). 
 
SET and RING Associated domain proteins 
The last type of domain that binds methylated CpGs is the SET and RING Associated (SRA) 
domain, see Figure 16. In humans the inverted CCAAT box-binding protein of 90 kDa 
(ICBP90) contains this domain, thus making it a MBP. ICBP90 binds to methylated CpG 
dinucleotides, and it does not seem to have much specificity for the adjacent sequences. The 
SRA domain, which is responsible for the binding of the methylated CpGs, is also the 
domain, which can bind to a HDAC and make a complex that targets promoter regions of 
various tumour suppressors (Unoki, Nishidate et al. 2004). The SRA domain can also 
recognize and bind to hemimethylated DNA under replication, where it recruits DNMT1 to 
methylate the complementary strand. Experiments with the murine analog of ICBP90, has 
shown that the SRA domain can also bind to DNMT3a and DNMT3b and cause silencing 
(Meilinger, Fellinger et al. 2009). Because of its involvement in different complexes it is 
suggested that ICBP90 is a part of the link between histone modifications, DNA methylation 
and chromatin structure (Unoki, Brunet et al. 2009).  
 
Figure 16: SET and RING Associated domain protein, showing the ubiquitin-like domain (UbL), Polybromo 
homology domain (PHD), SRA domain, and RING domain (Unoki, Brunet et al. 2009). 
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DNA HYPOMETHYLATION 
Hypomethylation is a decrease in the level of DNA methylation, compared to the normal 
state, either at a specific CpG dinucleotide, at a group of CpG nucleotides or in the entire 
genome (Laird, 2003). In the healthy genome most CpG islands are unmethylated, leading to 
expression of the associated genes. The lone CpGs scattered throughout the rest of the DNA, 
are on the contrary mostly methylated (Williamson, Christodoulou 2006, Wilson, Power et al. 
2007). Demethylation of the lone CpGs causes a general increase in the gene expression (Szyf 
2005). The genome of a cancer cell has in comparison with a normal cell a decrease in the 
m5C content of 20-60 % (Wilson, Power et al. 2007). This is mainly due to hypomethylation 
of the coding regions and introns of the genes. Demethylation of repetitive sequences is also 
important, since they alone accounts for 20-30 % of the human genome. Genome 
hypomethylation can occur early in the cancer development and accumulate through the 
different tumourigenic steps (Esteller 2009). The overall level of hypomethylation is neither 
specific for all cancer types in general nor within each cancer type (Wilson, Power et al. 
2007), but there are some cancer type-
specific differences in the frequency of 
hypomethylation of certain genomic 
sequences (Ehrlich, Hopkins et al. 2003). 
Figure 17 shows the consequences of global 
hypomethylation. The sequences which are 
most affected by cancer-specific DNA 
hypomethylation is; highly repeated 
sequences, moderate repeated sequences 
and unique sequences. Hypomethylation in 
these sequences all cause misregulations, 
such as abnormal expressions or tumour 
progression (Ehrlich 2002).  
Highly repeated sequences 
The expression, highly repeated sequences, refers to the fact that a sequence is present in 
multiple copies in the genome. The highly repeated sequences can be divided into 
heterochromatin repeats and interspersed repeats (Ehrlich 2002). The heterochromatin 
domains of the chromosomes are in general very condensed, which prohibit access of the 
Figure 17: Global hypomethylation have consequences
such as retrotransposition of DNA segments, oncogene
activation and chromosome instability. The dark spheres 
are methylated CpGs and the light spheres are 
unmethylated CpGs. Modified after (Taylor 2006). 
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binding factors and they are therefore transcriptionally silenced. A large amount of 
heterochromatin surrounds the functional chromosome structures, such as centromeres and 
telomeres. The smaller heterochromatin domains are interspersed throughout the 
chromosome. Heterochromatin is important in the maintenance of genome stability and 
regulation of gene expression during development and cellular differentiation (Grewal, 
Moazed 2003). Large parts of the heterochromatin near the centromeres and telomeres consist 
of tandem repeats (King, Cummings 1997), which are repeated copies of the same sequence 
which follow each other (Campbell, Reece 2005). One type of tandem repeats, which is 
affected by hypomethylation, is the satellite DNAs composed of oligonucleotide sequences 
(Ehrlich 2002). Especially, hypomethylation of centromeric satellite (Satα) on chromosome 1 
and hypomethylation of centromere adjacent, called juxacentromeric, heterochromatin on 
chromosome 1 and 16 are observed in several cancer types. These cancers are also observed 
together with rearrangement of the chromosomes, where either chromosome 1 are gaining an 
extra copy of the long arm, or the loss of the long arm on chromosome 16, both of which 
leads to genomic instability (Ehrlich, Hopkins et al. 2003). Wong et al. (2001) found a similar 
correlation and suggested that hypomethylation alters the interaction between the CpG-rich 
satellite DNA and chromatin proteins. This leads to a less dense heterochromatin formation, 
damage and aberrant chromosome formation (Wong, Lam et al. 2001). Experiments have 
shown that approximately half of the patients with Wilms tumours, a type of pediatric kidney 
tumours, have hypomethylation of satellite 2 (Sat2) in chromosome 1 (Szyf 2005). Sat2 is the 
main component of juxacentromeric heterochromatin, and is highly methylated in normal 
postnatal somatic tissues (Ehrlich, Buchanan et al. 2001). Another experiment showed that 
90% of Wilms tumours had hypomethylation of Satα (Szyf 2005).  
Another kind of highly repeated sequences are the interspersed repeats (Ehrlich 2002), which 
are repeated DNA sequences scattered throughout the genome (Smit 1996). The interspersed 
repeats consist of transposable elements, which are methylated, hence inactive, in the healthy 
genome. If they are methylated, they become capable of copying and integrating themselves 
into different parts of the genome. Hypomethylation of interspersed repeats can thereby cause 
activation of the promoters in the nearby areas of the transposable elements. This can lead to 
an altered level of transcriptional factors and/or modification of the expression of growth 
regulating genes. Researchers furthermore believe that unmethylated transposable elements 
induce mutations and aberrant combinations of the chromosomes, which result in a less dense 
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chromatin structure. Three types of transposable elements exist in the human genome: DNA 
transposons, retrotransposons and endogenous retroviruses. The two latter are the most 
investigated in connection to hypomethylation and cancer. Long interspersed nuclear element 
(LINE) is a type of retrotransposons and is therefore capable of moving copies of themselves 
into other parts of the DNA. This is done by transcription to RNA, followed by reverse 
transcriptase and then relocation and integration of the new copy into another part of the 
genome (Wilson, Power et al. 2007). One type of LINE subfamily, LINE-1, which consists of 
more than 4x105 copies and constitutes about 15 % of the genome, are found to have cancer-
associated hypomethylation (Ehrlich 2002). These sequences encode one type of RNA-
binding proteins and a protein for reverse transcriptase and endonuclease. If LINE-1 
sequences are activated they can be copied, moved and inserted into another part of the DNA 
such as tumour suppressors or oncogenes (Takai, Yagi et al. 2000). Retrotransposition of 
repeated LINE-1 sequences disrupts the DNA stability, because of the branched structure. 
Therefore, the instable DNA tends to recombinate with accessible elements found in the 
genome. Several cancer types have some translocations and insertions of these 
retrotransposable elements. LINE-1 sequences are found hypomethylated in most urethelial 
cancers and occurs in early stages of tumourigenesis (Florl, Lower et al. 1999).  
Moderate repeated sequences 
The moderate repeated sequences especially occur in the form of retrotransposons, such as 
human endogenous retroviruses (HERVs) (Ehrlich 2002). The structure of HERVs is similar 
to retroviruses, but lacks a functional gene (Wilson, Power et al. 2007). HERVs are highly 
methylated in healthy tissues (Ehrlich 2002), but when they are hypomethylated, they are 
often associated with transcriptional expression (Wilson, Power et al. 2007). Expression 
generally takes place in germ cell cancers. Testicular cancer and some cancers originating 
from somatic cells may be detected as retroviral proteins in the blood circulation. These can 
be used as biomarker (Hoffmann, Schulz 2005).  
Unique sequences 
Unique sequences are single-copy genes, and in connection with cancer it is primarily the 
following three gene types, which are hypomethylated: growth regulatory genes, 
developmentally critical genes and tissue specific genes. The latter could be germ cell-specific 
tumour antigen genes, like the melanoma antigen (MAGE) gene family (Wilson, Power et al. 
2007), which is found over-expressed in some kinds of cancers (Szyf 2005). The 
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hypomethylated promoter region of MAGE-A1 is connected to hepatocarcinoma (Xiao, Chen 
et al. 2005).  
DNA HYPERMETHYLATION 
Hypermethylation is an increase in the 
level of DNA methylation, compared to 
the normal state, either at a specific 
CpG dinucleotide or at a group of CpG 
nucleotides (Laird, 2003). 
Hypermethylation is often concentrated 
at the CpG islands in promoter regions 
of house-keeping and tumour suppressor 
genes (Clark, Melki 2002), thereby 
affecting a smaller part of the genome 
than hypomethylation does (Ehrlich, 
2002). Methylation of the promoters 
causes inactivation of the genes and 
possible loss of control over cellular growth, leading to uncontrolled cell division and thereby 
cancer (Luczak, Jagodzinski 2006). Figure 18 illustrates the consequences of CpG 
hypermethylation. It is still unclear if hypermethylation is a primary or secondary event of 
gene silencing, but it is apparent that it is a key element in the loss of gene function and 
cancer (Baylin, Herman 2000). It has been suggested that hypermethylation is critical in 
maintaining the gene in the inactive state, and therefore contributes to sustaining the cancer 
(Clark, Melki 2002). Hypo- and hypermethylation are in general independent of one another, 
even though they may emerge due to a similar abnormality (Erhlich, 2005).  
The genes that most often undergo hypermethylation during carcinogenesis are genes 
associated with DNA repair (BRCA1, MGMT), apoptosis (DAPK, TMS1), drug resistance, 
detoxification, differentiation, angiogenesis, metastasis and genes regulating the cell cycle 
(p16INK4a, p15INK4a, RB, p14ARF). See Appendix III for an overview of genes, which, when 
hypermethylated, cause cancer. Among the genes commonly hypermethylated in breast 
cancer is p16INK4a (Das, Singal 2004). This gene encodes cyclin-dependent kinase inhibitor 
(CDKN) that regulates the transition from G1- to S-phase in the cell cycle. Occurrence of 
Figure 18: Regional hypermethylation of the CpG
islands has consequences such as inactivation of tumour
suppressor and DNA repair genes. The dark spheres are
methylated CpGs and the light spheres are unmethylated
CpGs. Modified after (Taylor 2006). 
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hypermethylation in the first exon and promoter of p16INK4a is observed in vitro and in 20-
30% of primary breast cancers (Yang, Yan et al. 2001).  
Traditionally, cancer has only been associated with genetic mutations, but hypermethylation, 
like other epigenetic changes, is often a part of the changes in the genome. There have been 
observed cancers without mutations, but with hypermethylation. This suggests that promoter 
hypermethylation alone can cause cancer. Because of this observation, hypermethylation has 
been included as a mechanism, which is able to inactivate both alleles and thereby the gene 
(Clark, Melki 2002). The importance of this is not to be neglected; a study has shown that 
homozygous disruption of the Hic1 is lethal in mice, whereas the heterozygous, Hic1+/-, is 
not. Mice with Hic1+/- could survive, but if the wild-type allele were hypermethylated, they 
were likely to develop late onset cancer, since both alleles were inactivated (Baylin, Herman 
2000). 
An increase in protein synthesis of DNMT1 is significantly correlated with hypermethylation 
of the promoter regions of tumour suppressor genes in cancer (Luczak, Jagodzinski 2006). 
Agoston et al. (2005) revealed an increase of DNMT1 in breast cancer tissue, due to loss of 
their destruction domain in the N-terminal and thus lack of degradation activity. This inability 
to degrade DNMT1, may have led to an increase of hypermethylation in tumour suppressor 
genes, since DNMT1 is the major agent in DNA methylation (Agoston, Argani et al. 2005), 
which then have extended the genome abnormalities (Luczak, Jagodzinski 2006). Many 
studies have identified genes that are hypermethylated in individual cancer types. A study by 
Esteller et al. (2001) examined the distribution of promotor hypermethylation in 12 genes 
from 15 different cancer tissues. Most of the cancer types were tested for methylation on the 
12 genes, exceptions are the ones marked with N.D. in Table 2  (Esteller, Corn et al. 2001). 
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Table 2: 12 different genes have been investigated for hypermethylation in tumour tissue from 15 different 
types of human cancer. The table shows, in percent, how frequently the specific genes are hypermethylated in 
each cancer type and also how many tests they are based upon. Colour coding is as follows: 0-9%, 10-19%,  
20-29%,  30-39%, 40-49%,  50-100%. Based upon (Esteller, Corn et al. 2001).   
 
p16INK4a    p14ARF  p15INK4b MGMT hMLH1 BRCA1 GSTP1 DAPK CDH1 TIMP-3 p73 APC 
Colon 37%, 
41/110 
28%, 
37/132 
0%, 
0/19 
39%, 
127/323 
44% 
15/34 
0%, 
0/18 
4%, 
1/23 
13%, 
2/23 
N.D. 27%, 
6/22 
0%, 
0/10 
18%, 
20/108 
Breast 17%, 
11/66 
0%, 
0/20 
0%, 
0/16 
0%, 
0/36 
0%, 
0/10 
13%, 
11/84 
31%, 
24/77 
7%, 
1/15 
42%, 
37/88 
27%, 
8/29 
0%, 
0/15 
5%, 
1/19 
Ovary 18%, 
4/22 
5%, 
1/20 
N.D. 
0%, 
0/23 
N.D. 
19%, 
11/58 
0%, 
0/10 
9%, 
2/23 
N.D. N.D. N.D. 
0%, 
0/20 
Uterus 20%, 
6/29 
16%, 
4/25 
N.D. 
0%, 
0/17 
43%, 
24/56 
N.D. 
0%, 
0/20 
N.D. N.D. N.D. N.D. N.D. 
Lung 31%, 
28/89 
6%, 
4/62 
0%, 
0/21 
21%, 
18/83 
0%, 
0/20 
4%, 
1/22 
9%, 
2/21 
16%, 
10/64 
N.D. 
19%, 
4/21 
0%, 
0/22 
0%, 
0/17 
Head-Neck 27%, 
26/95 
4%, 
1/25 
N.D. 
32%, 
37/116 
N.D. N.D. 
0%, 
0/106 
18%, 
17/92 
N.D. N.D. N.D. 
0%, 
0/10 
Leukemia 1%, 
1/150 
5%, 
1/20 
62%, 
93/150 
6%, 
2/31 
6%, 
3/51 
0%, 
0/19 
0%, 
0/10 
9%, 
8/86 
40%, 
30/75 
N.D. 
31%, 
11/35 
N.D. 
Lymphoma 48%, 
12/25 
0%, 
0/22 
24%, 
6/25 
25%, 
15/61 
N.D. N.D. 
2%, 
1/47 
72%, 
21/29 
N.D. N.D. 
30%, 
3/10 
N.D. 
Brain 30%, 
3/10 
9%, 
2/22 
N.D. 
34%, 
74/213 
0%, 
0/15 
N.D. 
5%, 
1/20 
N.D. N.D. 
26%, 
20/77 
0%, 
0/22 
0%, 
0/10 
Kidney 23%, 
6/25 
13%, 
5/38 
N.D. 
8%, 
1/12 
N.D. N.D. 
20%, 
8/35 
N.D. N.D. 
78%, 
28/36 
0%, 
0/10 
8%, 
1/12 
Bladder 9%, 
1/11 
5%, 
1/20 
N.D. 
4%, 
2/44 
N.D. N.D. 
0%, 
0/24 
9%, 
1/11 
N.D. N.D. N.D. 
10%, 
2/19 
Esophagus 33%, 
5/15 
8%, 
3/37 N.D. 
20%, 
3/14 N.D. N.D. 
7%, 
1/14 N.D. 
84%, 
26/31 N.D. 
N.D. 
 
15%, 
4/27 
Stomach 36%, 
8/22 
26%, 
31/118 
N.D. 16%, 
10/60 
32%, 
21/65 
N.D. 0%, 
0/22 
N.D. N.D. N.D. N.D. 34%, 
13/38 
Pancreas 39%, 
7/18 
0%, 
0/20 
N.D. 
11%, 
2/18 
N.D. N.D. 
0%, 
0/18 
N.D. N.D. N.D. N.D. 
33%, 
6/18 
Liver 15%, 
3/20 
0%, 
0/20 
N.D. 
0%, 
0/59 
5%, 
2/20 
0%, 
0/18 
65%, 
13/20 
0%, 
0/20 
N.D. 
5%, 
1/20 
N.D. 
33%, 
6/18 
  
The genes represented in Table 2 can be divided into: Tumour suppressor genes (p16INK4a, 
p15INK4b, p14ARF, p73, APC and BRCA1) DNA repair genes (hMLH1, GSTP1 and MGMT) and 
genes related to the metastasis and invasion (CDH1, TIMP3 and DAPK). These genes all have 
a CpG island in the 5’region, which in normal tissue is unmethylated. Esteller et al. (2001) 
showed that some of the genes were hypermethylated. An example is p16INK4a, which was 
hypermethylated in 17 % of the breast cancer cases and in 37 % of the colon cancer cases. 
The study showed that not all the genes were hypermethylated in the different cancer types. 
Actually only p16INK4a showed hypermethylation in all the investigated cancer types, ranging 
from 1% in leukaemia to 48% in lymphoma, but generally showing a high degree of 
hypermethylation (Esteller, Corn et al. 2001).  
CDH1, coding for proteins responsible for cell adhesion (Home Reference 2007), showed in 
general a high percentage of hypermethylation. The study showed that there was 
hypermethylation in CDH1 in 40-84% of the studied cancers. Based on this study, the p16INK4a 
and CDH1 could be of importance in detecting cancer, e.g. as biomarkers (Esteller, Corn et al. 
2001).   
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EPIGENETIC ALTERATIONS 
Epigenetic modifications, such as DNA methylation, histone modifications and chromatin 
remodelling, are known to be closely connected. The following paragraph will concern the 
interactions of these modifications and how they, when altered, can contribute to cancer.  
DNA methylation, histone modifications and chromatin remodelling are all mechanisms 
which implicate the conformation of the chromatin, and thereby the level of gene 
transcription. When different mechanisms, independent of one another, can affect the same 
thing, it is plausible to assume that they in some way are also interacting. One interaction 
which has been demonstrated is the connection between histone acetylation and DNA 
methylation. It is however uncertain how they exactly influence each other, and whether it is 
the histone deacetylation or the DNA methylation which initiates and steers the cooperation. 
DNA methylation may be the primary mark for gene silencing that initiates events leading to 
a condensed chromatin state. Another possibility is that histone deacetylation is as the initial 
event of gene silencing, which is followed by local DNA hypermethylation catalyzed by 
DNMTs. It is suggested that it could be both of them, but it is still not clarified (Vaissiere, 
Sawan et al. 2008). Beside this interaction, research on DNMTs and MBDs has shown that 
these enzymes enforce HMTs to modify the K9H3 (Ballesta, Esteller 2005). Furthermore, a 
strong relationship has been shown between covalent histone modifications and ATP 
dependent chromatin remodelling (Jones, Baylin 2007).  
Some epigenetic factors have more than one function which can cause alterations. NuRD/Mi-
2/CHD has both chromatin remodelling and HDAC activity, since remodelling of the 
nucleosomes can both facilitate the deacetylation of the histone tails and allow the access of 
repressors. This complex is also correlated with MBD2 and it is known to be associated with 
methylated DNA. Thus, the NuRD/Mi-2/CHD remodelling complex is thought to connect 
DNA methylation, histone modifications and chromatin remodelling, (Dobosy, Selker 2001) 
like ICBP90 also suggested to do (Unoki, Brunet et al. 2009). 
Figure 19 illustrates that the mechanisms, which affect gene silencing, are interacting with 
each other and can therefore not be observed independently, if the overall mechanism of gene 
silencing are to be comprehended. Even though some interactions have been shown between 
the different epigenetic mechanisms, the overall interactions are still to be investigated (Jones, 
Baylin 2007).  
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Figure 19: Interaction between DNA 
methylation, histone modifications and 
ATP-dependent chromatin remodelling in 
gene silencing. Factors such as DNA 
methyl tranferases (DNMTs), methyl-CpG-
binding proteins (MBPs), histone 
deacetylases (HDACs), histone 
methyltranferses (HMTs) and the 
nucleosome remodelling factors (NURFs) 
contribute to these alterations. Based upon 
(Jones, Baylin 2007). 
 
EPIGENETIC ALTERATIONS IN CANCER 
Earlier, cancer was seen as a disease only caused by genetic mutations. This perception has 
changed a lot over the last decades and it has become clear that in a few cancer cases, only 
epigenetic changes occur. Although the specific mechanisms and interactions have yet to be 
completely understood, the knowledge of this field is rapidly growing. One of the better 
understood areas of the epigenetic involvement in cancer development is the repression of 
tumour suppressor genes. This repression is usually caused by hypermethylation in the CpG 
islands in the promoter region of the tumour suppressor genes (Baylin, Ohm 2006), such as 
p16; see Figure 20 (A) and Figure 21.2 (Jones, Gonzalgo 1997). In addition to this 
mechanism, hypomethylation can also cause cancer. This occurs when the promoter region of 
the inactive protooncogene is hypomethylated and the gene therefore becomes active. This 
can induce uncontrolled cell growth and thereby cancer, see Figure 20 (B) (Baylin, Ohm 
2006).  
 
Figure 20: (A) Hypermethylation in the promoter region prevents the transcription factor from binding, and 
the tumour suppressor gene cannot be expressed. (B) Hypomethylation in the promoter region enables the 
binding of transcription factors to the promoter region and the protooncogene will thereby be expressed. Both 
scenarios lead to uncontrolled cell growth and cancer (Nelson 2008). 
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Studies have shown that epigenetic 
alterations can be some of the first steps in 
cancer development (Baylin, Ohm 2006). 
Methylation of the cytosine base raises the 
possibility of a genetic mutation of this 
base. These genetic mutations are normally 
corrected by the base excision repair system 
as a part of the demethylation process, but if 
this process fails, the genetic mutation 
might be able to cause cancer, see Figure 
21.1 (Prokhortchouk, Hendrich 2002). This 
kind of mutation usually occurs in p53 
(Jones, Gonzalgo 1997). Figure 21.3 
illustrates that global hypomethylation 
might be able to cause chromosomal 
instability, which can increase gene 
expression, but this mechanism is not very 
well understood (Baylin, Ohm 2006). 
When the tumour suppressor genes are 
repressed, whole pathways are affected. 
Such a pathway could be the signal 
transduction pathway, which in normal cells 
prevent tumourigenesis, see Figure 22. An epigenetic event might cause the activation of an 
oncogene and this leads to tumourigenesis via the oncongenic pathway. This is however 
prevented since the by-product, reactive oxygen species (ROS), of this pathway also interfere 
with the tumour suppressor pathway. In this pathway ROS causes DNA damage and thereby 
stimulate the activation of tumour suppressors, such as p16 and p53. The tumour suppressors 
can induce a tumour suppressor defence mechanism that leads the damaged cells to premature 
senescence. If the tumour suppressors are inactivated the damaged cells will not become 
senescent and this could lead to uncontrolled cell growth and cancer (Sun, Kannemeier et al. 
2007). 
Figure 21: The role of the 5-methylcytosine in cancer. 
1. Shows the C → T mutation that results from 
deamination of 5-methylcytosine. 2. Shows how 
methylation of the promoter region can cause 
inactivation of tumour suppressor genes. 3. Shows how 
global hypomethylation can cause cancer because of 
the chromosomal instability. The circles represent 
cytosines in CpG dinucleotides, open circles are 
unmethylated cytosines and solid circles are 
methylated cytosines. Tumour suppressor (T.S.), 
promoter (PRO) and long terminal repeat (LTR). 
modified after (Jones, Gonzalgo 1997). 
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Figure 22: This figure shows a simplification of a signal transduction pathway in normal cells. Activation of 
an oncogenic pathway leads to tumourigenesis. A by-product, reactive oxygen species (ROS), of the 
oncogenic pathway stimulates the tumour suppressor pathway, and this increases the amount of transcribed 
tumour suppressors, which lead the damaged cells to premature senescence. Based upon (Sun, Kannemeier et 
al. 2007). 
For cancer to develop both alleles of a tumour suppressor gene have to be inactivate and this 
can happen in many different ways, see Figure 23. Usually, many genes are silenced when a 
cancer develops, this suggests that these silences do not occur at random, but are caused by 
linked epigenetic events. The exact mechanism behind this phenomenon is however not yet 
understood (Baylin, Ohm 2006). 
 
Figure 23: The involvement of DNA methylation in inactivation of tumour suppressor genes. The blue boxes 
represent two alleles of a gene and the pink circles are methylation marks. Mutation (mut) and methylation are 
introduced after the first hit, whereas loss of heterozygosity (LOH) and methylation are introduced after the 
second hit. The four different end products all result in inactivation of tumour suppressor genes (Allis 2007). 
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In a specific type of colon cancer epigenetic and genetic mechanisms have been shown to 
cooperate. In this cancer type there is a genetic mutation on one allele of the gene that 
encodes the tumour suppressor p16. On the other allele an epigenetic alteration has silenced 
the gene, so no functional gene product can be produced at all, see Figure 23.b (Baylin, Ohm 
2006).  
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EPIGENETIC THERAPY 
Since cancer is such a widespread disease, much research is performed in the area. This 
includes the epigenetics, which is a promising mechanism in connection with gene therapy, 
since epigenetic changes, unlike the genetic changes, can be reversed. When reversed, crucial 
genes are reactivated or reinactivated, and their normal states are restored, which in theory 
should eliminate the cancer or stop it from further development (Oki Issa 2007). In order to 
find new methods to diagnose and treat cancer, epigenetic mechanisms have become highly 
considered. This paragraph will focus on the epigenetics therapeutics; DNMT and HDAC 
inhibitors, since these are the most investigated. There will further be looked into how the 
mechanisms of changed methylation patterns can be used as a biomarker, in the diagnostics 
and prognostics of cancer. 
DNA METHYLTRANSFERASE INHIBITORS  
The knowledge of DNA methylation in tumour suppressor genes dates about 30 years back, 
but it is only recently that this insight has been used in the therapy of cancer (Kurkjian, 
Kummar et al. 2008). Hypermethylation of the promoter region is a reversible epigenetic 
process, which can be controlled by biochemical manipulations. This makes the 
demethylation process a useful tool in therapy (Kirsanova, Cherepanova et al. 2009). Therapy, 
with DNMT inhibitors, can be divided into two different groups; nucleoside analogues 
inhibitors and non-nucleoside analogues inhibitors (Esteller 2009). 
 
Nucleoside analogues 
All the nucleoside analogues resemble cytidine, see Figure 24, and can therefore be 
incorporated into DNA or RNA, where they have their inhibitory effect (Kristensen, Nielsen 
et al. 2009). 
The nucleoside analogues 5’azacytidine (azacitidine) and 5’aza-2’-deoxycytidine (decitabine), 
were the first epigenetic drugs to be synthesized. Using these drugs in therapy is complicated, 
because they are chemically unstable in water and very toxic. Zebularine is a new synthesized 
drug, which is more stable than the azacitidine and decitabine. It also has a higher selectivity 
for cancer cells than for normal cells (Kristensen, Nielsen et al. 2009).  
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Figure 24: Cytidine analogues; azacitidine, decitabine (Christman 2002) and zebularine (Kirsanova, 
Cherepanova et al. 2009, Christman 2002) resemble the structure of cytidine. R means ribose and dR is 
deoxyribose. Based upon (Christman 2002). 
Azacitidine is transferred into the cell by a nucleotide specific transfer system and then 
activated by phosphorylation to become cytidinetriphosphate. It can then be incorporated into 
either DNA or RNA (Esteller 2009). This drug is also called a hypomethylating agent, 
because it only inhibits DNMT1 (Kurkjian, Kummar et al. 2008). Since DNMT1 is the major 
agent in the maintenance methylation and also is important in de novo methylation, inhibition 
of DNMT1 will prevent the attachment of methyl groups to the DNA strand (Allis 2007). The 
demethylation is, as mentioned, probably controlled by DNMT3a and DNMT3b and because 
these are not inhibited, DNA hypomethylation can occur normally. The drugs decitabine and 
zebularine are transferred into the cell by the same system as azacitidine, but because they are 
deoxyribonucleotides they can only be incorporated into DNA (Esteller 2009). Out of the 
three mentioned nucleoside analogues, it is only azatidine and decitadine, which have 
undergone clinical trials (Christman 2002) and they have shown disappointing results in 
relation to cancer treatment. In leukaemia the two drugs seem to have only a small effect, 
since decitabine and zebularine are still too toxic for doses large enough to reverse all the 
cancer cells. Using the two analogues as a drug in patients with myeloid plastic syndrome has 
on the contrary shown positive responses (Kurkjian, Kummar et al. 2008). From the trials it 
can be concluded that as a DNMT inhibitor, decitabine is by far the most effective 
(Kristensen, Nielsen et al. 2009).  
 
Non-nucleoside analogues 
The non-nucleoside analogues are not incorporated into either DNA or RNA, but are directly 
affecting the function of the DNMT enzymes (Kurkjian, Kummar et al. 2008). There are 
many different non-nucleoside analogues that, in the future, might be used in cancer therapy, 
but in this section only some representatives of the different inhibitor types will be examined. 
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S-adenosyl-Lornothine (Sinefungin) is an analogue to the methyl donor SAM, with which it 
shares a very similar structure. Sinefungin reacts in the same way as SAM during the DNA 
methylation, but it does not have a free methyl group that can be donated to the DNA. Thus 
when sinefungins bind to the DNMT, it prevents the binding of SAM and therefore DNA 
methylation (Kirsanova, Cherepanova et al. 2009). Another non-nucleoside analogue is the 
DNMT inhibitor N-phthalyl-L-tryptophan (RG108) which seems to be specific for 
hypermethylated tumour suppressor genes (Kristensen, Nielsen et al. 2009). It is a small 
molecule which is inhibiting the active site of DNMT1 (Kurkjian, Kummar et al. 2008). It 
appears to be less toxic than some of the nucleoside analogues, including azacitidine and 
decitabine (Kristensen, Nielsen et al. 2009), and has a longer half life than some of the other 
DNMT inhibitors, e.g. 20 times longer half life than azacitidine. The major active constituent 
of green tea, epigallocatchin-3-gallate (EGCG) has also been shown to inhibit DNMTs 
(Kurkjian, Kummar et al. 2008).  
The effects of azatidine, decitabine, zebularine, RG108 and EGCG have been compared in a 
study. It showed that all other drugs than RG108, to some extend was toxic and that all, 
except EGCG, exhibited hypomethylating properties (Esteller 2009). The non-nucleoside 
analogues seem to affect DNA methylation in a small degree, so their mild activity may be 
considered only to be used as a part of cancer therapy (Kurkjian, Kummar et al. 2008). 
DNA methylation and histone deacetylation are both contributory factors in gene silencing, so 
today researchers try to combine the DNMT inhibitors and the HDAC inhibitors in the 
treatment of cancer (Kristensen, Nielsen et al. 2009). 
HISTONE DEACETYLACE INHIBITORS  
If HDAC is over-expressed the balance, between acetylation and deacetylation on the histone, 
is disturbed.  The consequence of this is a closed chromatin structure that allows permanent 
repression of a gene, such as a tumour suppressor. This can lead to cancer and in order to 
prevent this, therapeutic methods can be taken in to use, e.g. inhibition of the HDAC.  
The site of the inhibition is the zinc containing catalytic domain of the HDAC (Bicaku, 
Marchion et al. 2008). This active site fits the lysine side chain of the histone in a cylindrical 
pocket during deacetylation (Wang, Helquist et al. 2005), but when it is inhibited, the lysine 
side chain do not fit and deacetylation does not occur (Bicaku, Marchion et al. 2008). In order 
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to inhibit the HDAC enzyme, a small molecule should fit into the cylindrical pocket and 
chelate the zinc cofactor (Butler, Kozikowski 2008). Since HDACs also interact with non-
histone proteins, it can be a challenge only to inhibit deacetylation in the histones during 
cancer treatment (Kristensen, Nielsen et al. 2009). Furthermore, inhibitors with a zinc binding 
group (ZBG) can inhibit other zinc containing enzymes, than HDACs. For this reason it is 
important to synthesize inhibitors with affinity for the specific HDAC responsible for cancer 
development. This has been found to be a challenge, because the cylindrical pocket and the 
active site of the different HDAC classes are very alike (Butler, Kozikowski 2008). However 
instead of designing drugs with specificity for the active site, the drugs are designed to have 
specificity for the linings of the cylindrical pocket, which have much less homology between 
the HDACs (Kristensen, Nielsen et al. 2009, Butler, Kozikowski 2008). Because all the 
HDACs has the same general structure around the active site, most HDAC inhibitors consist 
of three functional domains, see Figure 25, which each interacts with a part of the HDACs 
(Mai, Altucci 2009). 
 
Figure 25: The three functionary domains in histone deacetylation inhibitors. CAP is the surface recognition 
unit, CU the connection unit and ZBG the zinc binding group (Mai, Altucci 2009). 
The ZBG domain binds to the HDAC by forming bonds to the zinc in the active site. Most 
inhibitors that are currently in clinical trials bind by reversible hydrogen bonds, but also 
irreversible inhibitors that bind covalently, are known. The linker and connecting unit tie the 
ZBG to the surface recognition domain, called CAP, through the cylindrical pocket. The CAP 
domain is where the specificity for the different HDAC enzymes is expressed (Butler, 
Kozikowski 2008), thus the inhibitors are structurally very different from each other in this 
domain, see Figure 26. This makes it possible to categorize them into four classes, based on 
their chemical properties (Gottlicher, Minucci et al. 2001): Hydroxamic acids, short-chain 
fatty acids, benzamides and cyclic peptide (Kristensen, Nielsen et al. 2009).  
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Figure 26: Some chemical structures of histone deacetylases inhibitors. SAHA is the only one that is 
approved for treatment, and the rest are in clinical trials. Colour codes represent the major domains of the 
inhibitors: red is CAP domain, green is conecting unit domain, blue is zinc binding group domain and black is 
the linker (Mai, Altucci 2009). 
So far only one HDAC inhibitor has been approved for cancer treatment (Kristensen, Nielsen 
et al. 2009). This inhibitor is the suberolyanilide hydroxamic acid (SAHA), which works by 
binding of its CAP domain to the specific HDACs and binding of its ZBG to the zinc ion in 
the active site of the HDAC. Also Trichostatin A (TSA) has been shown to be an effective 
cancer treatment, but due to its side effects it has not yet been put through clinical trials (Mai, 
Altucci 2009) 
Short-chain fatty acids, such as valproic acid, have been shown to inhibit growth of several 
cancers. The mechanism behind this is not fully clarified, but two suggestions have been 
proposed; that the carboxylic act as a ZBG or that the short-chain fatty acid competes with 
acetyl during the acetylation process (Mai, Altucci 2009). 
The benzamides differ a great deal from the other inhibitors, in relation to the ZBG domain. 
The ZBG end consists of a 2’-aminoanilide moiety that acts as a weak chelating group. This 
group can interact with the zinc ion in the active site of the HDACs. The two synthesized 
drugs in this class are both undergoing clinical trials (Kristensen, Nielsen et al. 2009). 
Unlike the other HDAC inhibitors, it is not possible for the cyclic peptides to directly interact 
with the zinc ion of the HDAC (Mai, Altucci 2009). Instead, the cyclic peptide romidepsin, is 
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activated by a reduction of the disulfide bond, after which it can inhibit the HDAC 
(Kristensen, Nielsen et al. 2009). 
All these inhibitors are relying on chelation of the zinc cofactor in the HDACs. This means 
that HDACs without zinc cannot be affected during deacetylation (Kristensen, Nielsen et al. 
2009). Only eleven out of at least eighteen human HDAC enzymes are zinc dependent, which 
means that there are still many possibilities to be explored for cancer treatment (Kristensen, 
Nielsen et al. 2009, Butler, Kozikowski 2008, Yang, Seto 2003).  
 
The development of cancer therapeutics within the epigenetic area has provided the basis for 
further studies. Hopefully the arrival of new cancer treatment agents, and identification of 
new active sites will make it possible to improve safety and efficiency of cancer drugs 
(Kurkjian, Kummar et al. 2008). 
 
METHYLATION BIOMARKERS 
Both hypo- and hypermethylation entail an alteration in the methylation level, which can give 
rise to the development of cancer. These epigenetic changes may be as important as the 
genetic changes in the carcinogenesis (Hopkins, Burns et al. 2007). Altered methylation levels 
could therefore be an event, which could be used as a biomarker in the prognostic and 
diagnostics of cancer (Wilson, Power et al. 2007). Great amount of investigation are, and has 
been, performed to induce hypo- or hypermethylation as a clinical tool, but until now, no 
DNA-methylation-based molecular test kit has been approved for diagnostic purposes by the 
U.S. government food and drug administration (Mulero-Navarro, Esteller 2008). To be 
considered as a biomarker in clinical diagnostics the marker must fulfil the following two 
demands: The marker should be an early and common event in the disease and should be able 
to distinguish the target condition from the healthy state or from other diseases. Furthermore a 
diagnostic assay for detection of the biomarker must be able to retain the molecular change in 
a background of normal cells or DNA (Wilson, Power et al. 2007). The applicability of a 
biomarker is assessed on the diagnostic accuracy of the assay. The accuracy is determined 
from the level of sensitivity and specificity. The sensitivity is defined as the probability of the 
assay giving a true positive individual, a positive assay result. High sensitivity means that the 
ability of the assay to identify the sick individuals, is good. The specificity is defined as the 
probability of the assay to give a true negative individual, a negative assay result. High 
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specificity means that the ability of the assay to identify the healthy individuals, is good 
(Bendsen 2009). Markers with high specificity for a cancer type can be considered as 
potential screening markers and can be used in risk assessment. Markers that are specific to 
multiple cancers can be considered as prognostic indicators, monitoring responses on therapy 
or other diagnostic applications (Mulero-Navarro, Esteller 2008). 
Hypomethylation as a biomarker has the disadvantage of not having a homogeneous level of 
methylation between individuals, or between the different tissues in one individual. There is, 
in addition, observed an overlap between DNA methylation levels in healthy and cancerous 
tissues, of the same type. Because of this overlap it is difficult to detect whether the level of 
hypomethylation is normal or abnormal. Furthermore it is still to be investigated, if 
hypomethylation is the source of, result of or whether it maintains the disease (Wilson, Power 
et al. 2007). 
Studies made on methylation patterns have shown that hypomethylation of specific DNA 
repeat elements or genes, are detectable in risk groups. Focusing on this, could therefore be a 
way of detecting cancer, however there is still a requirement for the processes to be further 
investigated before it can be considered as a biomarker (Wilson, Power et al. 2007). 
Hypermethylation in CpG islands is thought to be a future molecular marker for human 
cancer. This is due to the fact that when methylation happens within promoters of specific 
tumour suppressors (Shi, Wang et al. 2007), it results in no or only little expression of the 
associated gene (Cottrell 2004). Reduced expression leads to a weakened control of cell 
proliferation, which can induce cancer. A lot of investigation in this area has already led to a 
long list of genes which are hypermethylated in several tumour types. The predicted 
usefulness of DNA methylation as a biomarker is high, due to several unique advantages. One 
of these properties is that many DNA methylation marks are specific for tumour cells and is 
therefore not present in normal tissue. Furthermore all tumours have multiple aberrantly 
methylated loci, some of which are present in multiple tumour types and others only in 
specific types. A combination of these markers will make it possible to give a tumour specific 
diagnosis (Shi, Wang et al. 2007). Third, the methylation pattern and the underlying DNA 
strand are very stable (Cottrell 2004) and can be obtained from a wide variety of sources 
(Mulero-Navarro, Esteller 2008). This make the methylation pattern an ideal target for PCR 
or other amplification methods. Another important aspect is the early state at which 
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methylation is induced in tumour development. This makes it possible to predict the 
development of cancer, years before it is evidently present (Shi, Wang et al. 2007).  
During the past decade several methylated loci have been identified. Even though they all 
have potential as tumour biomarkers, only a few are tumour specific and this limits the 
amount of utilized genes in clinical treatment (Shi, Wang et al. 2007). One marker, which has 
shown promising results, is the gene; GSTP1, which is hypermethylated, thus inactive, in the 
promoter area in 80-90 % of prostate cancer cases (Mulero-Navarro, Esteller 2008). GSTP1 
codes for the enzyme glutathione-S-transferase-pi (Hopkins, Burns et al. 2007), which 
belongs to a class of enzymes that protect the cell from electrophilic compounds. They 
therefore have an important role in the cellular defence against the genotoxic effect from 
many carcinogens and oxidative species (Jones and Brooks, 2006). In a study by Lin et al. 
(2001) it was investigated whether reactivated GSTP1 shared similar effect as the tumour 
suppressor genes, which, when restored to their normal unmethylated condition, inhibit 
tumour growth. The study showed that reactivated GSTP1, did not suppress tumour 
progression, which indicates that it cannot be used as a therapy method. In addition, it is 
suggested that GSTP1 inactivation may leave the cells vulnerable for additional mutation, 
caused by carcinogens, which induce a growth advantage even after reactivation of GSTP1 
(Lin, Tascilar et al. 2001). This, however, does not exclude GSTP1 as a promising biomarker, 
since it may be capable of discriminating between prostate cancer and benign prostatic 
hyperplasia (BPH) (Hopkins, Burns et al. 2007), which is one of the most challenging 
problems in connection with prostate cancer diagnostic (Mommsen et al., 2005). In a novel 
study Dumache et al. (2009) investigated the presence of promoter hypermethylation of 
GSTP1 in 37 patients with histological diagnosed prostate cancer and 34 patients with the 
diagnosis of BPH. They found that 35 of the prostate cancer patients had hypermethylation of 
the promoter of GSTP1, and that none of the samples from the BPH patients had this altered 
methylation pattern (Dumache, Puiu et al. 2009). Studies have so far shown a promising 
future for the use of GSTP1 as a DNA-based biomarker. However, a few studies also showed 
that GSTP1 promoter hypermethylation was present in noncancerous prostatic tissue 
(Hopkins, Burns et al. 2007). The incongruence could be a result of differences in the used 
assay and which specific region of the GSTP1 CpG island there is targeted in the study, since 
differences in this can cause substantial variations in the resulting sensitivity (Lehninger, 
Nelson et al. 2008). The number of investigated cancer tissues is also an important factor in 
the evaluation of a study. Large-scale studies investigating the distribution of GSTP1 
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promoter methylation in prostate cancer could therefore be able to clarify the significance of 
the methylation pattern in prostate cancer, compared to normal tissue. Incongruence between 
studies is not restricted to investigations concerning GSTP1, but is a recurring problem when 
new biomarkers are to be studied. To manage this there is a need for cross-laboratory 
comparisons of different methodologies, development of standardized quality control 
materials for assays and a standard reporting format should be implemented (Mulero-Navarro, 
Esteller 2008).  
Even though, the number of aberrantly epigenetically regulated genes continues to grow, only 
a few methylation biomarkers are as informative as GSTP1 (Mulero-Navarro, Esteller 2008). 
To identify future biomarkers large-scale screening of aberrant epigenetic events can be used 
to identify specific epigenetic fingerprints for different types of cancers (Lin, Tascilar et al. 
2001). If a methylation pattern is found to be specific for one cancer type, it is furthermore 
important to investigate whether the exact methylation pattern is consistently detectable, 
without using an invasive procedure. If this is not the case, there is a low possibility of the 
biomarker being used in screening tests (Hopkins, Burns et al. 2007).  
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DISCUSSION 
In general, research in the epigenetic field has progressed in the last decade, but the 
mechanisms are still not completely unraveled. In this report we have examined the epigenetic 
mechanisms; DNA methylation, histone modifications and chromatin remodelling. 
Furthermore, we have investigated how these mechanisms might be connected and their 
involvement in cancer. 
The different epigenetic mechanisms have been studied thoroughly, but usually separately. 
This results in a lack of knowledge of how these mechanisms interact, and how they impact 
on each other, but some suggestions regarding these interactions have been presented. Even 
though the proposed interactions might not be completely correct, they may provide a basis 
for subsequent investigation.  
Suggestions for specific mechanisms have also been presented, even though they neither are 
fully understood. The demethylation mechanism in this report is a proposal for an 
unexplained process. The study by Métivier et al. (2008) proposes that the demethylation 
process consists of a deamination of an m5C, which is repaired by the base excision system to 
an unmethylated cytosine. We find the proposed process acceptable, since it is based on 
experiments and combines known mechanisms. One of the known mechanisms is the DNA 
repair activity of the MBD4, which is suggested to be a part of the base excision repair 
system, occurring in the demethylation process. We can use the proposed process to 
understand other mechanisms like hypomethylation, since this could be induced by an 
upregulation of the demethylation process. This shows that it is not always important to 
understand the details of a mechanism; sometimes an insufficient explanation can still be used 
to describe interrelations with other mechanisms or the observed consequences.  
Different studies have shown a connection between changes in the epigenetic code and the 
development or maintenance of cancer. Their results have however not provided sufficient 
information to explain the exact involvement. Such a study is e.g. the one performed by 
Esteller et al. (2001), where it was proposed that there is a connection between 
hypermethylation of certain genes and cancer. The study examined 12 genes in 15 different 
cancer types, thereby providing an insight in the prevalence of hypermethylation in cancer. 
Only the CpG islands in the 5’region was examined for hypermethylation, so the study did not 
provide any information about other epigenetic changes, such as histone modifications and 
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chromatin remodelling that could also have been of importance. Many studies like this 
provide data, which detects a connection between an epigenetic alteration and cancer, but 
omit to eliminate, or include, other factors that could be determining for the outcome of the 
result. Further, the studies are often based on limited datasets and are sometimes not 
performed in human cells, which could make the results nontransferable and thus the 
conclusions questionable.  
When considering the usefulness of epigenetic therapy, it is important to remember that 
cancer rarely develops because of one defect in our body. Cancer is mostly the result of many 
errors, where an epigenetic change can be one of them. Epigenetic therapy could reverse this, 
but if cancer is already developed, other defects, such as mutations, could maintain the 
diseased state. Furthermore, it could be of importance at what point the epigenetic changes are 
introduced, since this could affect how the cancer develops. It is therefore interesting to 
investigate when different epigenetic changes occur in the development of cancer and how the 
epigenetic and genetic changes interact and impact each other, since this information also 
could influence the choice of therapy. Epigenetics and genetics have long been considered 
separately, so it is still unclear how they are linked and in which ways they impact each other. 
These uncertainties make it difficult to predict how well cancer therapy, targeting only the 
epigenetic changes, can restore the healthy state. It is observed that cancer exist without 
genetic changes, and these cases could therefore be treatable with epigenetic therapy. 
Unfortunately, this kind of cancer is rare. If the epigenetic and genetic changes are closely 
connected, it could be interesting to investigate how epigenetic therapy influences genetic 
changes.  
Scientists are very optimistic about the future of using changed methylation patterns as a 
biomarker. One of the promising properties is that many DNA methylation marks are specific 
for tumour cells and are therefore not present in normal tissue. However, there has to our 
knowledge, not been performed any larger studies of the specificity and sensitivity of a 
methylation biomarker. There is therefore still many years of investigation before such a 
biomarker could be implemented in ordinarily clinical use. It does not seem like there is an 
accordance between different cancer types and their methylation pattern. Such a correlation 
would have made the identification of changed methylation patterns easier. On the other hand, 
these differences can be used in the development of biomarkers that are specific for one 
cancer type. A biomarker could also include methylation patterns of several genes as well as 
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other epigenetic changes. Biomarkers, which involve many genes, would be harder to find 
due to the complexity of the pattern of epigenetic changes. This could however be a very 
effective biomarker. 
There have been synthesized several drugs, which were designed to inhibit different 
epigenetic mechanisms. Unfortunately, none of them has shown promising results in cancer 
treatment. One of the reasons is that the drugs are too toxic, when used in amounts high 
enough to influence the cancer cells. The problem lies in the fact that the drugs also influence 
healthy cells. Therefore we find it important to investigate new therapy methods, which only 
target cancer cells and more specifically, only target the epigenetically changed gene and not 
the entire genome. Another reason why the synthesized inhibitors are ineffective could be that 
the proposed epigenetic mechanism is not the true mechanism. This would mean that the 
different inhibitors, synthesized to target specific processes, will not affect the actual 
mechanism. A hypothetical example could be if the DNMTs were not responsible for DNA 
methylation, then the DNMT inhibitors would not influence the methylation pattern. This 
example underlines the importance of further investigation in the epigenetic field, since that 
could lead to a better understanding of the different factors that impact the mechanism. More 
knowledge about these factors could also facilitate the development of more effective 
therapies.  
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CONCLUSION 
Epigenetics is a part of the normal cell function where it, among others, is involved in the 
regulation of gene silencing, transcription and replication. The regulation is controlled by 
mechanisms, such as DNA methylation, histone modifications and chromatin remodelling, 
which change the chromatin conformation. The DNA methylation is catalyzed by DNMTs, 
which attach methyl groups to the 5-position carbon in the cytosine. This is followed by the 
binding of MBPs to the methylated DNA, which further modifies the chromatin structure. 
Histone modifications are introduced by changes in the prevalence of acetylation, 
phosphorylation, methylation and ubiquitylation of the histone tails, and this influences the 
conformation of the chromatin. In chromatin remodelling, different complexes use the energy 
of ATP to change the structure of the chromatin. All of these mechanisms constitute the 
overall epigenetic code that determines which genes are active and which are silenced. In 
normal cells this is exemplified by activation of tumour suppressor genes and inactivation of 
oncogenes. Abnormal epigenetic changes can disrupt normal cell activity and could lead to 
cancer. The interactions between epigenetic changes in the development of cancer are not 
well studied, but some connections have been found. One example is phosphorylation of 
H3S10 that increases the activity of HAT and the transcriptional activity is thereby amplified. 
Another example of a connection is that the DNMTs and MBDs increase methylation on 
H3K9. Even though examples of correlations between the epigenetic mechanisms have been 
found, the overall context is not known. 
Epigenetic changes are, unlike genetics, reversible. This gives the opportunity of using 
epigenetic therapy in cancer treatment. The purpose of the DNMT inhibitors and HDAC 
inhibitors is to reactivate the silenced tumour suppressor genes and thereby restore the cell 
activity. The inhibitors synthesized so far have not shown promising results. Further 
investigation could lead to inhibitors with specificity for the genes with epigenetic changes. 
The abnormal changes in cells could be used as biomarkers in the diagnosis and prognosis of 
cancer. At the moment scientists are investigating the possibility of using the changed patterns 
of DNA methylation in cancer cells as biomarkers. This however, requires that the difference 
in DNA methylation patterns is explicit between normal and cancer cells. At present, the 
therapies and the biomarkers are too unspecific to be used clinically. More knowledge about 
the epigenetic changes and the way they interact is therefore needed to develop therapies and 
biomarkers with higher specificity.  
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FUTURE PROSPECTS 
Future studies with focus on the connection between DNA methylation, histone modification 
and chromatin remodelling in cancer, would give a more detailed view on how important 
these epigenetic mechanisms are in the development of cancer. These investigations could 
provide a better and more nuanced basis for the development of epigenetic therapies and new 
ways of diagnosing cancer.  
Investigations and clinical trials with epigenetic drugs have, as mentioned, not shown 
promising results so far. We expect to see more research in this field in the future and this will 
hopefully bring positive results. This could possibly be achieved by synthesizing new drugs 
that are more specific for cancer cells and thereby not as toxic as some of the present drugs. 
The drugs could be encased and only released in the cancer cells, thus not affecting the 
healthy cells. This might be done by targeting the drugs to specific receptors, on the surface of 
the cancer cell. The medicine could also be specific for one gene instead of the whole 
genome. In this report, we have focused on DNMT and HDAC inhibitors, which are based on 
the idea of reactivating silenced tumour suppressor genes and DNA repair genes. We could 
also imagine drugs that inhibit the HAT and thereby the formation of active oncogenes. Using 
epigenetic drugs in the treatment of cancer is expected in the future, but we only think that the 
epigenetic treatment will be a supplement to the traditional cancer therapy. Using epigenetic 
changes as biomarkers in prognosis and diagnosis of cancer seem, on the other hand, to have a 
promising future. Since epigenetic changes in some cases occur before the development of the 
actual tumour, the epigenetic biomarkers could be used as a preventive means. We expect that 
epigenetic biomarkers will be implemented in cancer diagnostics, within 10-15 years. The 
progression of new knowledge within the epigenetic field and the future possibilities, for 
epigenetics to be used in cancer treatment and diagnostics, are some of the aspects making 
this field so interesting. 
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APPENDIX I - ABBREVIATIONS 
AKAP12:   A kinase anchor protein12 
APC:  Adenomatous polyposis 
coli 
Azacitidine:  5’azacytidine 
BPH:  Benign prostatic 
hyperplasia 
BRCA1:     Breast cancer 1 
BRG1:      Brahma-related gene 1 
BRM:      Brahma  
BTB:   Bric-a-brac, Tramtrack, 
Broad-complex 
CASP8     Caspase-8 
CDH1:     Cadherin 1 
CDKN:   Cyclin-dependent kinase 
inhibitor 
CpG:               Cytosine phosphate 
guanine  
DAPK:   Death-associated protein 
kinase 
Decitabine:   5’aza-2’-deoxycytidine 
DNMT:     DNA methyltransferases 
DNMT3L:   DNA methyltransferase 3-
Like  
EGCG:     Epigallocatchin-3-gallate 
GSTP1:   Glutathione S-transferase P 
1 
H:        Histone 
HAT: Histone acetyltransferase 
HDAC:     Histone deacetylase 
HERV:  Human endogenous   
retrovirus 
Hic1:  Hypermethylated in 
cancer 1 
hMLH1:     Human Mut L homologue 
HMT:      Histone metyltransferase 
ICBP90:   Inverted CCAAT box-
binding protein of 90 kDa  
ING1: Inhibitor of growth 1 
INI1:      Integrase interactor 1.  
INO80:     Inositol requiring 80 
ISWI:      Imitation switching 
K:        Lysine 
KBS:   Kaiso binding site, 
TCCTGCNA 
KISS1: Kiss-1 metastasis-
suppressor 
LATS2: Large tumour suppressor 
2 
LINE-1:   Long interspersed nuclear 
element 1 
LTR:      Long terminal repeat 
m5C:      5-methylcytosine 
MAGE:     Melanoma antigen 
MBD:   Methyl-CpG-binding 
domain 
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MBP:   Methyl-CpG-binding 
protein 
MeCP2:   Methyl-CpG-binding 
protein 2 
MGMT:   O-6-methylguanine-DNA 
methyltransferases 
MLH1:     Mut L homologe 1 
MTA:      Metastasis-associated 
MTA1:  Metastasis tumor antigen 
1 
Np95:   Name of a protein: 
Nuclear protein of 95 kDa  
NuRD/Mi-2/CHD: Nucleosome 
remodelling histone 
deacetylase/Men-in-
Black2/chromo-helicase 
ATPase DNA binding  
NURF:   Nucleosome remodelling 
factors 
p14ARF :   Protein 14 alternate 
reading frame 
p15INK4a :   Protein 15 inhibitor of 
cyclin dependent kinase 
4a 
p16INK4a:   Protein 16 inhibitor of 
cyclin dependent kinase 
4a 
p53:       Protein 53 
p73:       Protein 73 
PCR:   Polymerase Chain 
Reaction 
PHD:   Polybromo homology 
domain 
POZ/BTB:   Poxvirus zinc finger 
domain/Bric-a-brac, 
Tramtrack, Broad-
complex 
PTEN:  Phosphatase and tensin 
homolog 
R:        Arginine 
RASSF1: Ras association domain 
family member 1 
RB:       Retinoblastoma 1 
RB:       Retinoblastoma protein 
RG108:    N-phthalyl-L-tryptophan 
RING:  Really interesting new 
gene 
ROS:      Reactive oxygen species 
S:        Serine 
SAHA:   Suberolyanilide 
hydroxamic acid  
SAM:      S-adenosyl-L-methionine 
Sat2:      Satellite 2 
Satα:      Satellite α 
SET:   Su(var)3-9, Enhancer-of-
zeste,Trithorax 
Sinefungin:   S-adenosyl-Lornothine 
SMAD4:    SMAD family member 4 
SNF2:      Sucrose nonfermenting 2  
SNF5/INI1:   Sucrose nonfermenting 5/ 
integrase interactor 1 
SNF5:      Sucrose nonformenting 5 
Page 64 of 67 
 
SOCS1:  Suppressor of cytokine 
signal 1 
SRA:      SET and RING-associated 
STK1:  Serine/threonine kinase 
11 
Suv39h:   Supressor of variegation 
3-9 homolog 
SWI/SNF:   Switching/sucrose 
nonformenting 
TIMP3:   Tissue inhibitor of 
metalloproteinase 3 
TMS1:   Target of methylation-
induced silencing 
TP53: Tumour protein P53  
TSA:      Trichostatin A  
Ub:       Ubiquinone 
UbL:      Ubiquinon 
VHL: von Hippel-Lindau 
WWOX: WW domain containing 
oxidoreductase 
ZBG:      Zinc binding group 
ZBTB:   Zinc finger and BTB 
domain containing protein 
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APPENDIX II – ATP-DEPENDENT CHROMATIN REMODELLING 
Human ATPase dependent remodelling complexes, their families, subunits and functions (Wang, 
Allis et al. 2007). 
 
Family and Complexes Complex function 
   
   
   
   
   
   
   
   
  
SW
I/
SN
F 
Fa
m
ily
 
BAF 
PBAF 
BRM 
BRG1-complex I 
BRG1-complex II 
EBAFa 
EBAFb 
Tumour suppressor, cell-  
cycle progression, DNA 
replication, development, 
differentiation, elongation, 
signaling, splicing, DNA-
damage repair 
   
   
   
   
IS
W
I 
Fa
m
ily
  
 
ACF/WCRF 
 
CHRAC 
 
RSF 
 
WICH 
 
SNF2H/Cohesin 
NURF 
X-chromosome regulation, 
cohesion, embryonic 
development and 
differentiation, 
transcriptional activation 
and repression, DNA 
replication, DNA 
repair response 
   
N
uR
D
/M
i-
2/
C
H
D
   
   
   
   
   
 F
am
il
y 
NuRD/Mi-2/CHD Tumour suppressor, 
transcriptional repression 
and silencing, 
transcriptional activation, 
pluripotency 
of embryonic stem cell 
   
   
IN
O
80
 F
am
ily
 
INO80 
TRRAP/Tip60 
SRCAP 
transcriptional repression 
and activation, cell cycle 
checkpoint, double strand 
break DNA repair system 
and base excision repair 
system 
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APPENDIX III – HYPERMETHYLATION IN CANCER 
Genes commonly hypermethylated in human cancers and their role in tumour development 
(Luczak, Jagodzinski 2006, Das, Singal 2004) 
 
Gene Role in tumour development Cancer type 
AKAP12 signal transduction gastric 
APC Deranged regulation of cell proliferation, cell migration, 
cell adhesion, cytoskeletal reorganization, and 
chromosomal stability 
 
Colorectal 
BRCA1 Implicated in DNA repair and transcription activation breast, ovarian 
CASP8 apoptosis neuroblastoma 
CDH1 Increasing proliferation, invasion, and/or metastasis 
 
breast, prostate, 
colorectal 
 
CDKN2A cyclin-dependent kinase inhibitor 
 
lymphoma 
CDKN2B cyclin-dependent kinase inhibitor 
 
leukemia 
DAPK1 Calcium/calmodulin-dependent enzyme that 
phosphorylates serine/ 
threonine residues on proteins; Suppression of apoptosis 
lung, B-cell 
lymphomas 
GSTP1 
 
prevention of oxidative DNA damage prostate 
ING1 cell growth and apoptosis lung 
KISS1 chemotaxis and invasion 
 
breast 
 
LATS2 
 
androgen receptormediated 
transcription 
 
Breast, colon, 
gastric 
MTA1s Inhibits cell signaling through affecting estrogen receptors breast 
Page 67 of 67 
 
  
MGMT Methyltransferase Several cancers 
MLH1 Defective DNA mismatch repair and gene mutations colon 
PTEN negatively regulating AKT/PKB signaling pathway 
 
colorectal 
RASSF1 Loss of negative regulator control of cell proliferation 
through inhibition of G1/S-phase progression, in the cell 
cycle. 
kidney 
RB1 represses the transcription of cellular genes 
 
retinoblastoma 
SMAD4 cell proliferation colorectal 
SOCS1 negative regulator of cytokine signaling 
 
pancreatic 
STK11 signal transduction Lung 
TIMP3 inhibitor of the matrix metalloproteinases 
 
colon, renal, brain 
 
TP53 cell cycle regulator leukemia 
WWOX 
 
transcription regulation, protein degradation 
 
lung, breast, 
bladder 
VHL  promotes angiogenesis Renal, 
carcinoma 
 
 
